[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 91 of about 91
1. Kietpeerakool C, Srisomboon J, Prompittayarat W, Kanjanavaha P, Peuwsai R, Dheerakul C: Can adenocarcinoma in situ of the uterine cervix be predicted before cervical conization? Asian Pac J Cancer Prev; 2006 Oct-Dec;7(4):522-4
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can adenocarcinoma in situ of the uterine cervix be predicted before cervical conization?
  • This study was undertaken to determine the effectiveness of the Papanicolaou (Pap) smear, colposcopically-directed biopsy (CDB), and endocervical curettage (ECC) in preconization detection of adenocarcinoma in situ (AIS) of the uterine cervix.
  • Women, whose cervical conization specimens contained adenocarcinoma in situ without any associated invasive lesion at Chiang Mai University Hospital between March 1998 and March 2006, were reviewed.
  • According to the histological type of AIS, glandular abnormality suspected from preoperative evaluation was noted in 20 women (70.4%) who had pure AIS.
  • Among women with mixed AIS/HSIL, only 12 women (50.0%) had preoperative evaluation suggesting glandular abnormality.
  • These data demonstrate that the sensitivity of combining Pap smear, CDB and/or ECC in detecting glandular lesions before conization containing AIS appears to be suboptimal.
  • Further study concerning the improvement of detecting AIS before conization is warranted to select the most appropriate diagnostic conization method for such lesions.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma in Situ / diagnosis. Cervix Uteri / pathology. Conization. Uterine Cervical Neoplasms / diagnosis


2. Li C, Rock KL, Woda BA, Jiang Z, Fraire AE, Dresser K: IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. Mod Pathol; 2007 Feb;20(2):242-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression.
  • Adenocarcinoma in situ of the uterine cervix remains a diagnostic challenge in a small proportion of cases.
  • This suggests a need for biomarker that may be of help in establishing the diagnosis.
  • The aim of this study was to evaluate the potential of insulin-like growth factor-II mRNA-binding protein 3 and cyclin-dependent kinase inhibitor p16(INK4a) as biomarkers for adenocarcinoma in situ.
  • Forty-four samples of adenocarcinoma in situ from 40 patients and 23 control cases of benign uterine cervix were included in this study.
  • Cytoplasmic immunoreactivity for insulin-like growth factor-II mRNA-binding protein 3 was identified in 41 (93%) adenocarcinoma in situ samples, among which, 29 (71%), 10 (24%), and 2 (5%) samples showed insulin-like growth factor-II mRNA-binding protein 3 positive staining in 50% or more, >5 to <50 and <5% of adenocarcinoma in situ lesional cells, respectively.
  • Immunohistochemical reaction intensity for insulin-like growth factor-II mRNA-binding protein 3 was found to be strong in 34 adenocarcinoma in situ samples, intermediate in five, and weak in two.
  • All 23 control cases were negative for insulin-like growth factor-II mRNA-binding protein 3. p16(INK4a) expression was identified in all of the adenocarcinoma in situ samples with intermediate staining intensity seen in seven samples and strong in the remainder.
  • Our findings demonstrate significant expression of insulin-like growth factor-II mRNA-binding protein 3 and p16(INK4a) in adenocarcinoma in situ as compared to benign endocervical glands, suggesting that expression of these biomarkers may be helpful in the distinction of adenocarcinoma in situ from benign endocervical glands, particularly in difficult borderline cases.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma in Situ / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Neoplasm Proteins / metabolism. RNA-Binding Proteins / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Adult. Cervix Uteri / metabolism. Cervix Uteri / pathology. Female. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Middle Aged

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17192788.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins
  •  go-up   go-down


3. Srisomboon J, Kietpeerakool C, Suprasert P, Siriaunkgul S, Khunamornpong S, Prompittayarat W: Factors affecting residual lesion in women with cervical adenocarcinoma in situ after cone excisional biopsy. Asian Pac J Cancer Prev; 2007 Apr-Jun;8(2):225-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors affecting residual lesion in women with cervical adenocarcinoma in situ after cone excisional biopsy.
  • The objective of this study was undertaken to evaluate the factors affecting residual lesion in women with adenocarcinoma in situ (AIS) on cervical conization specimens.
  • The medical records of women with AIS who had no associated invasive carcinoma after cervical conization and underwent subsequent hysterectomy at Chiang Mai University Hospital were reviewed.
  • Thirteen (28.9%) women presented with AIS on Pap smear.
  • Twenty (44.4%) women had mixed lesions of AIS and squamous intraepithelial lesion on cervical specimens.
  • In conclusion, approximately one-third of women with AIS on cervical conization have residual lesion on subsequent hysterectomy specimens.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Neoplasm, Residual / pathology. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Biopsy. Carcinoma in Situ / epidemiology. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Female. Humans. Hysterectomy. Incidence. Neoplasms, Second Primary / epidemiology. Neoplasms, Second Primary / pathology. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696736.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


Advertisement
4. Gong L, Zhang WD, Liu XY, Han XJ, Yao L, Zhu SJ, Lan M, Li YH, Zhang W: Clonal status and clinicopathological observation of cervical minimal deviation adenocarcinoma. Diagn Pathol; 2010;5:25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal status and clinicopathological observation of cervical minimal deviation adenocarcinoma.
  • BACKGROUND: Minimal deviation adenocarcinoma (MDA) of the uterine cervix is defined as an extremely well differentiated variant of cervical adenocarcinoma, with well-formed glands that resemble benign glands but show distinct nuclear anaplasia or evidence of stromal invasion.
  • Thus, MDA is difficult to differentiate from other cervical hyperplastic lesions.
  • CONCLUSIONS: Diagnosis of MDA depends mainly on its clinical manifestations, the pathological feature that MDA glands are located deeper than the lower level of normal endocervical glands, and immunostaining.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Cell Differentiation. Chromosomes, Human, X. Receptors, Androgen / genetics. Uterine Cervical Neoplasms / genetics. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoembryonic Antigen / analysis. Case-Control Studies. Cell Proliferation. DNA, Viral / analysis. Female. Humans. Immunohistochemistry. In Situ Hybridization. Mosaicism. Neoplasm Invasiveness. Papillomaviridae / genetics. Polymerase Chain Reaction. Polymorphism, Genetic. Predictive Value of Tests. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Mol Pathol. 2001 Mar;10(1):24-33 [11277392.001]
  • [Cites] J Pathol. 2003 Dec;201(4):535-43 [14648656.001]
  • [Cites] Mod Pathol. 2004 Aug;17(8):962-72 [15143335.001]
  • [Cites] Am J Obstet Gynecol. 1975 Apr 1;121(7):971-5 [1115185.001]
  • [Cites] Biochim Biophys Acta. 1976 Oct 12;458(3):283-321 [1067873.001]
  • [Cites] Gynecol Oncol. 1980 Oct;10(2):125-33 [7461479.001]
  • [Cites] Pathology. 2008 Jun;40(4):392-5 [18446630.001]
  • [Cites] Am J Hum Genet. 1992 Dec;51(6):1229-39 [1281384.001]
  • [Cites] Mod Pathol. 1998 Jan;11(1):11-8 [9556417.001]
  • [Cites] Virchows Arch. 1998 Apr;432(4):315-22 [9565340.001]
  • [Cites] Int J Gynecol Pathol. 2005 Jul;24(3):296-302 [15968208.001]
  • [Cites] Diagn Cytopathol. 2006 Feb;34(2):119-23 [16511847.001]
  • [Cites] Development. 1987 Feb;99(2):187-96 [3652995.001]
  • (PMID = 20416098.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / DNA, Viral; 0 / Receptors, Androgen
  • [Other-IDs] NLM/ PMC2877003
  •  go-up   go-down


5. Sidoruk AA, Novik VI, Urmancheeva AF: [Clinico-morphological diagnosis of adenocarcinoma in situ of the cervix uteri]. Vopr Onkol; 2009;55(6):733-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinico-morphological diagnosis of adenocarcinoma in situ of the cervix uteri].
  • Clinical and morphological investigation involved 57 patients with adenocarcinoma in situ of the cervix uteri (poorly-differentiated (precancerous) cell carcinoma in situ (PAIS)--30; adenocarcinoma in situ (AIS)--27).
  • Predictions for PAIS histotype were confirmed in 83%, cytological findings--78%; AIS--52% and 58%, respectively.
  • Accuracy for PAIS and AIS biopsy was 52% and 32%, respectively.
  • However, our procedure failed to detect malignant process in 17.5% (PAIS--6 cases and AIS--4) which was established by use of smears (Feulgen).
  • [MeSH-major] Adenocarcinoma / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Vaginal Smears


6. Bhurgri Y, Nazir K, Shaheen Y, Usman A, Faridi N, Bhurgri H, Malik J, Bashir I, Bhurgri A, Kayani N, Pervez S, Hasan SH, Setna F, Zaidi SM: Patho-epidemiology of Cancer Cervix in Karachi South. Asian Pac J Cancer Prev; 2007 Jul-Sep;8(3):357-62
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patho-epidemiology of Cancer Cervix in Karachi South.
  • INTRODUCTION: The present study was conducted with the objective of examining descriptive epidemiological and pathological characteristics of cancer cervix in Karachi South, an all urban district population of Karachi, Pakistan.
  • METHODOLOGY: A total of 74 cases of cancer cervix, ICD-10 (International Classification of Diseases 10th Revision) category C53 were registered at the Karachi Cancer Registry, for Karachi South, during a 3 year period, 1st January, 1995 to 31st December 1997.
  • Cancer cervix accounted for approximately 3.6% of all cancers in females and was the sixth malignancy in hierarchy.
  • The morphological categorization was squamous cell carcinoma (86.5%), adenocarcinoma (10.9%) and adenosquamous carcinoma (2.6%).
  • There were no in-situ cases.
  • Approximately half the cancers (58.1%) had spread regionally and 8.1% to a distant site at the time of diagnosis.
  • CONCLUSION: The incidence of cervical cancer in Karachi South (1995-97) reflects a low risk population with a late presentation and a high stage disease at presentation.
  • It is suggested that cervical screening if implemented should focus on once a life time methodology involving 36-45 year old women.
  • A regular cervical screening program would require mobilization of considerable financial, structural and human resources along with training for personnel.
  • [MeSH-major] Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18159967.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


7. Little L, Stewart CJ: Cyclin D1 immunoreactivity in normal endocervix and diagnostic value in reactive and neoplastic endocervical lesions. Mod Pathol; 2010 Apr;23(4):611-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It may be difficult to distinguish reactive glandular lesions from adenocarcinoma in situ of the uterine cervix, and although several immunohistochemical markers have established value in this diagnostic setting, none is completely reliable.
  • Therefore, we investigated cyclin D1 staining in a series of 64 cervical biopsy specimens including examples of normal and reactive endocervical epithelium, adenocarcinoma in situ, stratified mucin-producing intraepithelial lesions, and invasive adenocarcinoma.
  • Thirteen specimens also included a component of high-grade cervical squamous intraepithelial neoplasia.
  • In contrast, most cases of adenocarcinoma in situ were completely negative and, therefore, cyclin D1 staining distinguished benign from neoplastic epithelial cells.
  • Although focal cyclin D1 expression was observed in 5/19 cases of adenocarcinoma in situ, the staining was associated with more marked cytological atypia precluding confusion with a reactive process.
  • In conclusion, cyclin D1 can be included within an immunohistochemical panel to aid in the distinction between reactive cervical glandular lesions and adenocarcinoma in situ.
  • [MeSH-major] Adenocarcinoma / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Cervix Uteri / metabolism. Cyclin D1 / biosynthesis. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20062011.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 136601-57-5 / Cyclin D1
  •  go-up   go-down


8. Maley SN, Schwartz SM, Johnson LG, Malkki M, Du Q, Daling JR, Li SS, Zhao LP, Petersdorf EW, Madeleine MM: Genetic variation in CXCL12 and risk of cervical carcinoma: a population-based case-control study. Int J Immunogenet; 2009 Dec;36(6):367-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic variation in CXCL12 and risk of cervical carcinoma: a population-based case-control study.
  • We conducted a population-based case-control study to test the hypothesis that common genetic variation in CXCL12 individual single nucleotide polymorphism (SNP) alleles and haplotypes] is associated with the risk of cervical carcinoma.
  • Cases (n = 917) were residents of western Washington State diagnosed with invasive squamous cell cervical carcinoma (SCC), invasive adenocarcinoma or adenosquamous carcinoma, or adenocarcinoma in situ of the cervix.
  • The minor allele of intronic SNP rs266085 was inversely associated with cervical cancer under a recessive genetic effects model (OR = 0.74, 95% CI: 0.56-0.98).
  • A stepwise procedure identified rs17885289, rs266085 and 3'-untranslated region (UTR) SNP rs266093 as the most parsimonious subset of SNPs necessary to define the haplotype inversely associated with cervical cancer risk in our study.
  • A 3'-UTR SNP, rs1801157, previously found to be related to HIV pathogenesis, was not associated with cervical cancer risk.
  • Further population-based studies are warranted to confirm these associations between genetic variation in CXCL12 and cervical cancer risk.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Mar 1;107(5):1761-7 [16269611.001]
  • [Cites] Tissue Antigens. 2006 Feb;67(2):127-33 [16441483.001]
  • [Cites] Int J Mol Med. 2006 Oct;18(4):785-93 [16964435.001]
  • [Cites] Int J Gynecol Cancer. 2007 Mar-Apr;17(2):478-83 [17362322.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jun;46(6):577-86 [17366619.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5056-62 [17785557.001]
  • [Cites] Cancer Sci. 2007 Nov;98(11):1652-8 [17894551.001]
  • [Cites] Oncol Rep. 2007 Dec;18(6):1583-7 [17982648.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2007;90:1-636 [18354839.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3532-9 [18451182.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1790-9 [18628433.001]
  • [Cites] BMC Genet. 2008;9:90 [19102730.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1117-21 [10613347.001]
  • [Cites] Eur J Neurosci. 2000 Jun;12(6):1857-66 [10886327.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2597-606 [12239174.001]
  • [Cites] Am J Epidemiol. 2003 Feb 1;157(3):218-26 [12543621.001]
  • [Cites] Nat Genet. 2003 May;34(1):70-4 [12692554.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):3-13 [12807939.001]
  • [Cites] Biostatistics. 2003 Oct;4(4):513-22 [14557108.001]
  • [Cites] Am J Hum Genet. 2004 Jan;74(1):106-20 [14681826.001]
  • [Cites] J Med Genet. 2004 May;41(5):e59 [15121787.001]
  • [Cites] J Mol Histol. 2004 Mar;35(3):233-45 [15339043.001]
  • [Cites] Nature. 1996 Aug 29;382(6594):829-33 [8752280.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jul;5(7):541-8 [8827359.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):1101-9 [9064327.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 1;19(4):381-6 [9833747.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] Immunol Rev. 2005 Feb;203:235-43 [15661033.001]
  • [Cites] Br J Haematol. 2005 Feb;128(4):493-5 [15686457.001]
  • [Cites] J Infect Dis. 2005 Mar 15;191(6):969-76 [15717274.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Exp Med. 2005 Apr 4;201(7):1069-75 [15809352.001]
  • [Cites] J Mol Biol. 2005 Apr 22;348(1):43-62 [15808852.001]
  • [Cites] Hum Mol Genet. 2005 Jun 15;14(12):1579-85 [15843397.001]
  • [Cites] Cancer Lett. 2005 Jul 28;225(2):261-6 [15978329.001]
  • [Cites] Lung Cancer. 2005 Sep;49(3):311-5 [15955592.001]
  • [Cites] Tissue Antigens. 2005 Oct;66(4):321-4 [16185329.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):276-9 [16249700.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):521-6 [16284526.001]
  • [Cites] Genes Immun. 2005 Dec;6(8):691-8 [16177829.001]
  • [Cites] Gene. 2006 Jun 7;374:174-9 [16626895.001]
  • (PMID = 19788587.001).
  • [ISSN] 1744-313X
  • [Journal-full-title] International journal of immunogenetics
  • [ISO-abbreviation] Int. J. Immunogenet.
  • [Language] ENG
  • [Grant] United States / NHGRI NIH HHS / HG / T32HG00035; United States / NCI NIH HHS / CA / CA112512-02; United States / NCI NIH HHS / CA / R01CA112512; United States / NCI NIH HHS / CA / R01 CA112512-02; United States / NCI NIH HHS / CA / P01 CA042792-219003; United States / NCI NIH HHS / CA / P01CA04279; United States / NCI NIH HHS / CA / R25 CA094880; United States / NCI NIH HHS / CA / CA112512-01; United States / NIEHS NIH HHS / ES / P30ES07033; United States / NHGRI NIH HHS / HG / T32 HG000035; United States / NCI NIH HHS / CA / CA112512-04; United States / NCI NIH HHS / CA / R01 CA112512-01; United States / NCI NIH HHS / CA / R01 CA112512-03; United States / NIEHS NIH HHS / ES / P30 ES007033; United States / NCI NIH HHS / CA / R01 CA112512-04; United States / NCI NIH HHS / CA / R25CA094880; United States / NCI NIH HHS / PC / N01-PC-35412; United States / NCI NIH HHS / CA / CA042792-219003; United States / NCI NIH HHS / CA / P01 CA042792; United States / NCI NIH HHS / CA / CA112512-03; United States / NCI NIH HHS / CA / CA112512-05; United States / NCI NIH HHS / CA / R01 CA112512-05; United States / NCI NIH HHS / CA / R01 CA112512
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / CXCL12 protein, human; 0 / Chemokine CXCL12
  • [Other-IDs] NLM/ NIHMS144226; NLM/ PMC2784202
  •  go-up   go-down


9. Graesslin O, Dedecker F, Collinet P, Jouve E, Urbaniack D, Leroy JL, Boulanger JC, Quéreux C: [Management of in situ cervical adenocarcinoma]. Gynecol Obstet Fertil; 2006 Dec;34(12):1178-84
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of in situ cervical adenocarcinoma].
  • [Transliterated title] Prise en charge de l'adénocarcinome in situ du col utérin.
  • The management of adenocarcinoma in situ of the cervix (ACIS) is difficult because it is often diagnosed in younger women who may wish to preserve their potential of fertility.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma in Situ / surgery. Colposcopy / methods. Reproduction. Uterine Cervical Neoplasms / surgery


10. Akiba Y, Kubushiro K, Fukuchi T, Fujii T, Tsukazaki K, Mukai M, Nozawa S: Is laser conization adequate for therapeutic excision of adenocarcinoma in situ of the uterine cervix? J Obstet Gynaecol Res; 2005 Jun;31(3):252-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is laser conization adequate for therapeutic excision of adenocarcinoma in situ of the uterine cervix?
  • AIMS: To determine the safety of uterine-preserving operations for adenocarcinoma in situ of the cervix.
  • METHODS: Fifteen cases of adenocarcinoma in situ (AIS) were diagnosed using neodymium:yttrium aluminum garnet (Nd:YAG) laser conization.
  • The accuracy of preconization histology or cytology was evaluated in 15 AIS cases.
  • In these AIS cases, we investigated how far the tumor was located from the squamocolumnar junction (SCJ) and the endocervix.
  • Fourteen cases of the 15 AIS-affected patients were treated using laser conization alone.
  • RESULTS: Precise agreement between preconization diagnosis and conization histology was seen in 46.7% (7/15) of the AIS cases.
  • In 14 of the 15 cases of AIS (93.3%), the tumor was adjacent to the transitional zone, within 3 mm of the SCJ, and in the other case (6.7%), the tumor was between 0 and 5 mm away from the SCJ.
  • None of the 15 patients showed any recurrence of AIS during follow up ranging from 15 to 75 months (43.1 months on average).
  • CONCLUSIONS: Women with AIS who want to preserve their fecundity might be treated with laser conization alone.
  • [MeSH-major] Adenocarcinoma / surgery. Cervix Uteri / surgery. Conization / methods. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15916663.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Young JL, Jazaeri AA, Lachance JA, Stoler MH, Irvin WP, Rice LW, Andersen WA, Modesitt SC: Cervical adenocarcinoma in situ: the predictive value of conization margin status. Am J Obstet Gynecol; 2007 Aug;197(2):195.e1-7; discussion 195.e7-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical adenocarcinoma in situ: the predictive value of conization margin status.
  • OBJECTIVE: We evaluated the impact of conization margin status on outcomes of patients diagnosed with cervical adenocarcinoma in situ.
  • STUDY DESIGN: A retrospective chart review identified patients at a University hospital from 1988-2006 with adenocarcinoma in situ (AIS) on conization.
  • Of patients with positive margins, 55% (12/22) were diagnosed with residual or recurrent disease, including 3 patients diagnosed with adenocarcinoma on hysterectomy.
  • Thirteen percent of patients with negative conization margins (6/46) were diagnosed with residual or recurrent disease, including 2 patients diagnosed with adenocarcinoma during follow-up.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma in Situ / pathology. Cervix Uteri / pathology. Conization. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17689647.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Kim JH, Park JY, Kim DY, Kim YM, Kim YT, Nam JH: The role of loop electrosurgical excisional procedure in the management of adenocarcinoma in situ of the uterine cervix. Eur J Obstet Gynecol Reprod Biol; 2009 Jul;145(1):100-3
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for adenocarcinoma in situ .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of loop electrosurgical excisional procedure in the management of adenocarcinoma in situ of the uterine cervix.
  • OBJECTIVES: To evaluate the occurrence of residual or recurrent disease after loop electrosurgical excisional procedure (LEEP) for adenocarcinoma in situ (AIS) of the uterine cervix.
  • STUDY DESIGN: Records of 78 patients with a histological diagnosis of AIS of uterine cervix on LEEP who were treated and followed at our center between 1992 and 2008 were, retrospectively, reviewed.
  • Of the 47 patients with negative margins, 30 underwent subsequent hysterectomy and residual AIS, including 1 invasive adenocarcinoma, was present in 17% (5/30) of patients.
  • Of the 31 patients with positive margins, 29 patients underwent subsequent hysterectomy and residual AIS, including 4 invasive adenocarcinomas, was present in 48% (14/29) of patients.
  • CONCLUSIONS: The incidence of residual disease in patients with negative margins after LEEP for AIS of the uterine cervix is low but not negligible.
  • However, positive resection margin carries a higher risk for residual AIS or occult invasive adenocarcinoma, warranting additional LEEP or hysterectomy in these patients.
  • [MeSH-major] Adenocarcinoma / surgery. Electrosurgery / methods. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Cervix Uteri / surgery. Female. Follow-Up Studies. Gynecologic Surgical Procedures / instrumentation. Gynecologic Surgical Procedures / methods. Humans. Hysterectomy. Incidence. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19428171.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 31
  •  go-up   go-down


13. Miller B, Dunn J, Dalrymple J, Krivak TC: Pelvic sidewall adenocarcinoma after definitive therapy for cervical adenocarcinoma in situ. Gynecol Oncol; 2005 Nov;99(2):489-92
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelvic sidewall adenocarcinoma after definitive therapy for cervical adenocarcinoma in situ.
  • BACKGROUND: Traditionally, hysterectomy is considered definitive therapy for cervical adenocarcinoma in situ (AIS) in women beyond childbearing.
  • CASE: A 45-year-old gravida 2, para 2 patient presented with cervical dysplasia and on pathology review of the large loop excision procedure cervical adenocarcinoma in situ was diagnosed.
  • Final pathology revealed adenocarcinoma in situ with negative margins.
  • A CT-guided biopsy of the mass was consistent with invasive adenocarcinoma of the endocervical type.
  • CONCLUSION: This case depicts another example of the unpredictable nature of cervical AIS.
  • Despite undergoing definitive surgery, a residual focus of disease may remain leading to invasive adenocarcinoma.
  • Close follow-up is required of all patients diagnosed with AIS because the disease is poorly understood.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma in Situ / surgery. Pelvic Neoplasms / pathology. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16054200.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Terada T: Simultaneous squamous cell carcinoma in situ and adenocarcinoma in situ of the uterine cervix in a 36-year-old Japanese woman. Arch Gynecol Obstet; 2010 Mar;281(3):527-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous squamous cell carcinoma in situ and adenocarcinoma in situ of the uterine cervix in a 36-year-old Japanese woman.
  • INTRODUCTION: Simultaneous occurrence of squamous cell carcinoma in situ (SIS) and adenocarcinoma in situ (AIS) is very rare in Japan.
  • CASE: The author reports a rare case of coexistence of SIS and AIS in a young Japanese woman.
  • A 36-year-old Japanese woman complained of abnormal uterine bleeding, and consulted to our hospital.
  • Colposcopic examination revealed irregular lesions in the cervix, and a biopsy showed simultaneous SIS and AIS.
  • The SIS corresponded to cervical intraepithelial neoplasm3, HGSIL, or carcinoma in situ, and AIS was typical AIS.
  • The SIS showed in situ atypical cells without stratification and polarity.
  • The AIS showed tubular or cribriform apparent AIS of mixed endocervical and intestinal type.
  • Most of the areas of SIS and AIS were separated but the two were occasionally seen to merge when involving the glands.
  • The Ki-67 labeling was 82% in the SIS and 78% in the AIS.
  • CONCLUSION: The author reported a Japanese case of combined SIS and AIS, so far infrequently reported in Japanese woman.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / pathology. Neoplasms, Multiple Primary / pathology. Uterine Cervical Neoplasms / pathology


15. Dedecker F, Graesslin O, Bonneau S, Quéreux C: [Persistence and recurrence of in situ cervical adenocarcinoma after primary treatment. About 121 cases]. Gynecol Obstet Fertil; 2008 Jun;36(6):616-22
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Persistence and recurrence of in situ cervical adenocarcinoma after primary treatment. About 121 cases].
  • [Transliterated title] Persistance et récidive des adénocarcinomes in situ après traitement: à propos d'une série rétrospective multicentrique de 121 cas.
  • OBJECTIVE: The aim of this study is to assess the results of conservative management of adenocarcinoma in situ (AIS) of the uterine cervix.
  • Patients with cervical invasive lesions were excluded.
  • General characteristics of population, diagnosis circumstances, treatment, histology and evolution were studied.
  • DISCUSSION AND CONCLUSION: Conservative surgery for patients with AIS could be considered in young patients but several conditions should be respected: careful follow-up after conservative treatment; cold knife conization; length of cone specimen greater than 25 mm and negative margins.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma in Situ / surgery. Neoplasm Recurrence, Local / prevention & control. Papillomavirus Infections / surgery. Uterine Cervical Neoplasms / surgery


16. Bull-Phelps SL, Garner EI, Walsh CS, Gehrig PA, Miller DS, Schorge JO: Fertility-sparing surgery in 101 women with adenocarcinoma in situ of the cervix. Gynecol Oncol; 2007 Nov;107(2):316-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility-sparing surgery in 101 women with adenocarcinoma in situ of the cervix.
  • OBJECTIVES: Cervical adenocarcinoma in situ (AIS) is a precursor of invasive disease that is increasing in incidence primarily among reproductive-age women of low parity.
  • Conization is an alternative to hysterectomy that allows future pregnancy, but has an inherent risk of residual AIS.
  • METHODS: Women diagnosed with cervical AIS who underwent primary fertility-sparing surgery with either loop excision or cold knife conization between 1993 and 2001 were identified at three institutions.
  • Patients 40 years of age and older and those undergoing hysterectomy within 12 months of diagnosis were excluded.
  • No invasive cervical adenocarcinomas were observed during the study interval.
  • CONCLUSION: Fertility-sparing surgery enables women with cervical AIS to achieve pregnancy with minimal risk of developing invasive disease during surveillance.
  • [MeSH-major] Adenocarcinoma / surgery. Conization. Fertility. Gynecologic Surgical Procedures / methods. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Carcinoma in Situ / surgery. Cohort Studies. Female. Humans. Hysterectomy. Medical Records. Parity. Population Surveillance. Pregnancy. Pregnancy Outcome. Reoperation. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17689593.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


17. Griffin D, Manuck TA, Hoffman MS: Adenocarcinoma in situ of the cervix in pregnancy. Gynecol Oncol; 2005 May;97(2):662-4
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in situ of the cervix in pregnancy.
  • INTRODUCTION: The number of patients diagnosed with adenocarcinoma in situ of the cervix has increased in the last decade.
  • CASES: In this report, we describe three patients diagnosed with adenocarcinoma in situ of the cervix during pregnancy.
  • DISCUSSION: The management of adenocarcinoma in situ of the cervix may include procedures which present substantial risks to an ongoing pregnancy and more conservative management may be warranted in many instances.
  • [MeSH-major] Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / surgery. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Adult. Carcinoma in Situ / diagnosis. Carcinoma in Situ / surgery. Female. Humans. Pregnancy


18. McCluggage WG, Shah R, Connolly LE, McBride HA: Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2. Int J Gynecol Pathol; 2008 Jan;27(1):92-100
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
  • Most cases of cervical adenocarcinoma in situ (AIS) and adenocarcinoma are of the usual or endocervical type.
  • However, intestinal types of AIS and adenocarcinoma exist.
  • With an intestinal-type adenocarcinoma in the cervix, the question may arise as to whether one is dealing with a primary cervical neoplasm or direct or secondary spread from an intestinal adenocarcinoma.
  • In organs such as the ovary, urinary bladder, esophagus, and gallbladder, intestinal-type glandular epithelium often expresses enteric markers, but this has hardly been studied in the cervix.
  • The purpose of this study was to investigate whether intestinal-type AIS and adenocarcinoma in the cervix express enteric markers and to ascertain whether these antibodies are of value in the distinction from a metastatic intestinal adenocarcinoma.
  • We compared the immunophenotype of these lesions with that of usual-type AIS and adenocarcinomain the cervix.
  • Cases included were AIS of usual type (n = 6), primary cervical adenocarcinoma of usual type (n = 6), AIS of intestinal type (n = 21), primary cervical adenocarcinoma of intestinal type (n = 3), primary cervical adenocarcinoma with signet ring cells (n = 2), and colorectal adenocarcinoma involving the cervix (n = 5).
  • Usual-type AIS was always diffusely CK7 positive, typically diffusely CEA and p16 positive, and always CK20 negative.
  • All usual cervical adenocarcinomas were diffusely CK7 and p16 positive, and all were immunoreactive with CEA.
  • Intestinal-type AIS was diffusely CK7 positive (all cases) and typically CK20 negative and diffusely CEA and p16 positive.
  • In addition, usual-type AIS adjacent to intestinal type was CDX2 positive in 13 of 21 cases.
  • The 3 cases of primary cervical intestinal-type adenocarcinoma were diffusely CK7 positive, focally or diffusely positive with CK20 and CDX2, and focally positive with CEA.
  • The foci of signet ring cells in the 2 primary cervical adenocarcinomas were diffusely CK7 and p16 positive and negative with CK20 and CDX2.
  • Colorectal adenocarcinomas involving the cervix were typically diffusely positive with CK20, CEA, and CDX2; negative with CK7; and negative or focally positive with p16.
  • Intestinal types of cervical AIS and adenocarcinoma exhibit a partial enteric immunophenotype, usually with diffuse expression of CDX2 and, in some cases, staining with CK20.
  • Although there is immunophenotypic overlap, focal staining with CK20 together with diffuse CK7 and sometimes p16 positivity helps to distinguish intestinal types of cervical adenocarcinoma from involvement by a colorectal adenocarcinoma; CEA and CDX2 are of no value in this regard.
  • CDX2 positivity in usual-type AIS adjacent to intestinal type and in occasional cases of pure usual-type AIS may be a reflection of early intestinal differentiation before this is morphologically apparent.
  • Using a set of cases of AIS diagnosed in a single institution over a 7-year period (77 usual type; 13 intestinal type), intestinal type was more likely to be associated with early invasive adenocarcinoma than usual type (31% vs 17%), suggesting that intestinal differentiation may be a risk factor for invasion in premalignant cervical glandular lesions.
  • [MeSH-major] Adenocarcinoma / metabolism. Homeodomain Proteins / biosynthesis. Intestinal Neoplasms / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoembryonic Antigen / biosynthesis. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Immunophenotyping. Keratin-20 / biosynthesis. Keratin-7 / biosynthesis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156982.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Carcinoembryonic Antigen; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


19. Zafar N, Balazs L, Benstein BD: Synchronous high-grade squamous intraepithelial lesion and adenocarcinoma in situ of cervix in a young woman presenting with hyperchromatic crowded groups in the cervical cytology specimen: report of a case. Diagn Cytopathol; 2008 Nov;36(11):823-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous high-grade squamous intraepithelial lesion and adenocarcinoma in situ of cervix in a young woman presenting with hyperchromatic crowded groups in the cervical cytology specimen: report of a case.
  • We report a 29-year-old woman who underwent routine gynecologic evaluation at a community clinic and had a cervical sample drawn for liquid-based cytologic evaluation.
  • At biopsy, the cervix contained synchronous squamous cell carcinoma in situ, secondarily involving endocervical glands, and neighboring adenocarcinoma in situ.
  • This case re-emphasizes the challenge associated with accurate evaluation of HCG at cytology, the significance of ancillary testing for surrogate markers of high-risk HPV (HR-HPV) infection, the need for adjunct testing for HPV-DNA in the setting of HCG at cervical cytology, and a recommendation to set up studies to evaluate the role of surrogate markers of HR-HPV infection in cytologic samples with HCG.
  • [MeSH-major] Adenocarcinoma / pathology. Cervical Intraepithelial Neoplasia / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18831021.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Hurrell DP, Jamison J, Dobbs SP, McCluggage WG: Cervical adenocarcinoma in situ recurring as vaginal adenocarcinoma 16 years after hysterectomy. Int J Gynecol Pathol; 2009 May;28(3):296-300
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical adenocarcinoma in situ recurring as vaginal adenocarcinoma 16 years after hysterectomy.
  • We report a case in which a vaginal adenocarcinoma was discovered in a 67-year-old woman 16 years after hysterectomy for cervical adenocarcinoma in situ.
  • Both the vaginal and cervical lesions exhibited morphologic and immunohistochemical (CDX2-positive) features of intestinal differentiation.
  • Linear array human papillomavirus genotyping demonstrated the vaginal adenocarcinoma to contain human papillomavirus 45.
  • We believe the vaginal adenocarcinoma to be related to the cervical adenocarcinoma in situ and to represent recurrence of this.
  • [MeSH-major] Adenocarcinoma / pathology. Cervical Intraepithelial Neoplasia / pathology. Neoplasm Recurrence, Local / pathology. Uterine Cervical Neoplasms / pathology. Vaginal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620950.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Xu JY, Hashi A, Kondo T, Yuminamochi T, Nara M, Hashi K, Murata S, Katoh R, Hoshi K: Absence of human papillomavirus infection in minimal deviation adenocarcinoma and lobular endocervical glandular hyperplasia. Int J Gynecol Pathol; 2005 Jul;24(3):296-302
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of human papillomavirus infection in minimal deviation adenocarcinoma and lobular endocervical glandular hyperplasia.
  • The human papillomavirus (HPV) is basically always detected in squamous cell carcinoma of the cervix and its precursors; a high incidence of HPV also has been reported in adenocarcinoma and adenocarcinoma in situ of the uterine cervix.
  • It is difficult to differentiate minimal deviation adenocarcinoma (MDA) from LEGH preoperatively or postoperatively by clinical and pathologic features.
  • As the control, HPV DNA was detected in all cases of squamous cell carcinoma and three of five cases of adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / virology. Neoplasms, Glandular and Epithelial / virology. Papillomaviridae / growth & development. Papillomavirus Infections / complications. Tumor Virus Infections / virology. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15968208.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


22. Dalrymple C, Valmadre S, Cook A, Atkinson K, Carter J, Houghton CR, Russell P: Cold knife versus laser cone biopsy for adenocarcinoma in situ of the cervix--a comparison of management and outcome. Int J Gynecol Cancer; 2008 Jan-Feb;18(1):116-20
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cold knife versus laser cone biopsy for adenocarcinoma in situ of the cervix--a comparison of management and outcome.
  • Eighty-two patients with adenocarcinoma in situ of the cervix managed at Royal Prince Alfred Hospital were reviewed and data were collected on those treated by cold knife cone biopsy (n= 38) and laser cone biopsy (n= 44).
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma in Situ / surgery. Conization / methods. Laser Therapy. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17506846.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Dede M, Gezginç K, Ulubay M, Alanbay I, Güran S, Yenen M: A breast cancer patient with pelvic and gastric malignancy after adjuvant tamoxifen treatment for breast cancer. Eur J Gynaecol Oncol; 2008;29(2):200
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As is known, tamoxifen therapy is related to endometrial proliferation, hyperplasia, polyp formation, invasive carcinoma and uterine sarcoma.
  • Gastric tumor, endometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with tamoxifen for breast cancer.
  • [MeSH-minor] Adenocarcinoma / chemically induced. Aged. Carcinoma in Situ / chemically induced. Endometrial Neoplasms / chemically induced. Female. Humans. Middle Aged. Stomach Neoplasms / chemically induced. Uterine Cervical Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18459568.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Selective Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


24. Geldenhuys L, Murray ML: Sensitivity and specificity of the Pap smear for glandular lesions of the cervix and endometrium. Acta Cytol; 2007 Jan-Feb;51(1):47-50
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity and specificity of the Pap smear for glandular lesions of the cervix and endometrium.
  • OBJECTIVE: To investigate the sensitivity and specificity of the Pap smear for detection of adenocarcinoma in situ of the cervix (AIS), endocervical adenocarcinoma (ECAC) and endometrial adenocarcinoma (EAC) as well as the overall specificity of the smear for detection of glandular lesions in general.
  • STUDY DESIGN: Computer records of the laboratory of the QE II Health Sciences Center, Halifax, were searched for patients who had AIS, ECAC or EAC diagnosed on histology between June 1, 1999, and May 31, 2001 and who had had a Pap smear within the preceding year.
  • Computer records were also searched for patients who had a Pap smear result consisting of suspicious or positive for AIS or adenocarcinoma (AC) with subsequent tissue diagnosis during the same time.
  • RESULTS: One hundred percent of patients with AIS, 80% with ECAC and 22% with EAC on histology had positive findings on a Pap smear performed within a year of the histologic diagnosis.
  • One hundred percent of patients with a Pap smear result consisting of suspicious or positive for AIS or AC and follow-up histology had a lesion on histology: 13% AIS, 13% ECAC, 37% EAC, 23% other AC, 10% high grade squamous lesion and 0.3% low grade squamous lesion.
  • It also confirmed the good sensitivity for glandular lesions of the cervix and the poor sensitivity for glandular lesions of the endometrium.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis. Papanicolaou Test. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears
  • [MeSH-minor] Carcinoma in Situ. Cervical Intraepithelial Neoplasia / diagnosis. Female. Humans. Sensitivity and Specificity. Uterine Hemorrhage / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer Screening.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17328495.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Odashiro AN, Odashiro DN, Nguyen GK: Minimal deviation endometrioid adenocarcinoma of the cervix: report of three cases with exfoliative cytology. Diagn Cytopathol; 2006 Feb;34(2):119-23
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal deviation endometrioid adenocarcinoma of the cervix: report of three cases with exfoliative cytology.
  • Three histologically confirmed minimal deviation endometrioid adenocarcinomas (MDEA) of the uterine cervix with cytologic evaluation by cervical scraping were reviewed.
  • The cytologic manifestations of those three cervical MDEAs overlapped, to some extents, with those of a cervical adenocarcinoma in situ and with those of a well-differentiated endometrial adenocarcinoma invading the cervix.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • (PMID = 16511847.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Lacour RA, Garner EI, Molpus KL, Ashfaq R, Schorge JO: Management of cervical adenocarcinoma in situ during pregnancy. Am J Obstet Gynecol; 2005 May;192(5):1449-51
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of cervical adenocarcinoma in situ during pregnancy.
  • OBJECTIVE: Adenocarcinoma in situ (AIS) is a precursor of invasive disease that is being more frequently diagnosed during the reproductive years.
  • The purpose of this study was to review our collective experience managing cervical AIS during pregnancy.
  • STUDY DESIGN: Retrospective medical record review of all women diagnosed with AIS during pregnancy from 1995 to 2004 at 3 academic institutions.
  • Five who received a diagnosis in the early second trimester underwent uncomplicated cold knife conization (CKC) at 14 to 19 weeks' gestation.
  • One patient undergoing postpartum CKC required radical hysterectomy for stage IB1 cervical adenocarcinoma.
  • CONCLUSION: Management of cervical AIS during pregnancy by early second trimester CKC is safe for mother and fetus.
  • [MeSH-major] Adenocarcinoma / surgery. Conization. Pregnancy Complications, Neoplastic / surgery. Uterine Cervical Neoplasms / surgery


27. Kennedy CM, Peterson LB, Galask RP: Erosive vulvar lichen planus: a cohort at risk for cancer? J Reprod Med; 2008 Oct;53(10):781-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine the occurrence of cancer, including vulvovaginal squamous cell carcinoma (SCC), among women after diagnosis of erosive vulvar lichen planus (LP).
  • RESULTS: A diagnosis of cancer was made in 5 women after diagnosis of erosive vulvar LP.
  • Of these, 1 had stage II vulvar SCC after treatment for stage IIB cervical cancer, and 2 with oral LP had subsequent diagnoses of oral or esophageal SCC.
  • The remaining 2 cancer diagnoses included cervical adenocarcinoma in situ and rectal adenocarcinoma.
  • Estimating the risk of SCC among women with vulvar LP is difficult because of the low prevalence of each disorder.

  • Genetic Alliance. consumer health - Vulvar cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19004404.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / 1K23 HD045769
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


28. Daniel A, Barreth D, Schepansky A, Johnson G, Capstick V, Faught W: Histologic and clinical significance of atypical glandular cells on pap smears. Int J Gynaecol Obstet; 2005 Dec;91(3):238-42
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 197(45.2%) patients had a clinically significant diagnosis including 40 with adenocarcinoma in situ (AIS) of the cervix and 48 with endometrial cancer.
  • CONCLUSION: AGC on a Pap smear is frequently associated with a clinically significant diagnosis.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / pathology. Endometrial Neoplasms / pathology. Genital Diseases, Female / pathology. Papanicolaou Test. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Cervical Cancer Screening.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202416.001).
  • [ISSN] 0020-7292
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. Rabelo-Santos SH, Villa LL, Derchain SF, Ferreira S, Sarian LO, Angelo-Andrade LA, do Amaral Westin MC, Zeferino LC: Variants of human papillomavirus types 16 and 18: histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in cervical smear. Int J Gynecol Pathol; 2006 Oct;25(4):393-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variants of human papillomavirus types 16 and 18: histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in cervical smear.
  • Human papillomavirus (HPV) genotypes cannot fully explain the histological diagnosis of women with glandular abnormalities detected by cervical smear.
  • Thus, this study was designed to analyze the distribution of HPV-16 and HPV-18 variants in women referred because of atypical glandular cells and adenocarcinoma in situ in their cervical smears and its association with histological results.
  • Twenty-four women with HPV-16 and 6 with HPV-18, selected from 160 women with cervical smears suggestive of glandular abnormalities, were included.
  • Among the 15 cases associated with the European variant, 14 (93%) presented squamous neoplasia and 1 (7%) invasive adenocarcinoma.
  • Asian-American HPV-16 variants were significantly associated with histological diagnosis of glandular neoplasia alone (odds ratio, 9.3 [1.4-60.2]) or associated with squamous neoplasia (odds ratio, 18.7 [1.5-232.3]).
  • [MeSH-major] Adenocarcinoma / virology. Cervical Intraepithelial Neoplasia / virology. Human papillomavirus 16 / genetics. Human papillomavirus 18 / genetics. Uterine Cervical Neoplasms / virology. Uterine Cervicitis / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16990718.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


30. Cohn DE, Morrison CD, Zanagnolo VL, Goist MM, Copeland LJ: Invasive cervical adenocarcinoma immediately following a cone biopsy for adenocarcinoma in situ with negative margins. Gynecol Oncol; 2005 Jul;98(1):158-60
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive cervical adenocarcinoma immediately following a cone biopsy for adenocarcinoma in situ with negative margins.
  • BACKGROUND: Cervical adenocarcinoma in situ is often diagnosed in younger women who may wish to preserve the potential for fertility.
  • Given that the rate of recurrent adenocarcinoma in situ is relatively low and the risk of invasive adenocarcinoma is extremely rare, conservative management in this population after a cone biopsy demonstrates negative margins has been accepted as an appropriate management strategy.
  • This case challenges the concept of conservative management of cervical adenocarcinoma in situ.
  • CASE: A 42-year-old G2P2002 with previously normal annual cervical cytology had a Pap smear demonstrating atypical glandular cells of uncertain significance.
  • A 1.5-cm lesion was noted at the endocervix, and a punch biopsy revealed adenocarcinoma in situ.
  • A large cold knife cone biopsy confirmed cervical adenocarcinoma in situ with negative margins.
  • Definitive therapy for in situ disease with an extrafascial hysterectomy was performed 12 days after conization, and demonstrated stage IB1 cervical adenocarcinoma.
  • CONCLUSION: Conservative management of cervical adenocarcinoma in situ after a cone biopsy with negative margins does not exclude the possibility of concurrent invasive cervical adenocarcinoma.
  • This case challenges the current balance between risk and benefit associated with the conservative management of cervical adenocarcinoma in situ.
  • [MeSH-major] Adenocarcinoma / pathology. Conization. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913738.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Austin RM, Onisko A, Druzdzel MJ: The Pittsburgh Cervical Cancer Screening Model: a risk assessment tool. Arch Pathol Lab Med; 2010 May;134(5):744-50
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Pittsburgh Cervical Cancer Screening Model: a risk assessment tool.
  • CONTEXT: Evaluation of cervical cancer screening has grown increasingly complex with the introduction of human papillomavirus (HPV) vaccination and newer screening technologies approved by the US Food and Drug Administration.
  • OBJECTIVE: To create a unique Pittsburgh Cervical Cancer Screening Model (PCCSM) that quantifies risk for histopathologic cervical precancer (cervical intraepithelial neoplasia [CIN] 2, CIN3, and adenocarcinoma in situ) and cervical cancer in an environment predominantly using newer screening technologies.
  • RESULTS: The PCCSM compares risk quantitatively over time for histopathologically verifiable CIN2, CIN3, adenocarcinoma in situ, and cervical cancer in screened patients for each current cytology result category and for each HPV result.
  • Prior history also alters the CIN2, CIN3, adenocarcinoma in situ, and cervical cancer risk for patients with common current cytology and HPV test results.
  • The PCCSM can also generate negative risk projections, estimating the likelihood of the absence of histopathologic CIN2, CIN3, adenocarcinoma in situ, and cervical cancer in screened patients.
  • CONCLUSIONS: The PCCSM is a dynamic Bayesian network that computes quantitative cervical disease risk estimates for patients undergoing cervical screening.
  • Continuously updatable with current system data, the PCCSM provides a new tool to monitor cervical disease risk in the evolving postvaccination era.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Early Detection of Cancer / methods. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Papanicolaou Test. Papillomavirus Infections / diagnosis. Risk Assessment. Risk Factors. Vaginal Smears

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20441506.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Dekker AH: Fostering acceptance of human papillomavirus vaccines. J Am Osteopath Assoc; 2006 Mar;106(3 Suppl 1):S14-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multivalent prophylactic human papillomavirus (HPV) vaccines currently in the late stages of clinical testing are safe, immunogenic, and efficacious; and phase 3 tests of a quadrivalent vaccine show that it is 100% effective at preventing HPV types 16 and 18-associated cervical intraepithelial neoplasia grades 2 and 3, adenocarcinoma in situ, and cervical cancer through 2 years of postvaccination follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16729556.001).
  • [ISSN] 0098-6151
  • [Journal-full-title] The Journal of the American Osteopathic Association
  • [ISO-abbreviation] J Am Osteopath Assoc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines; 0 / Viral Vaccines
  • [Number-of-references] 18
  •  go-up   go-down


33. Aximu D, Azad A, Ni R, Colgan T, Nanji S: A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics. Int J Gynecol Pathol; 2009 Mar;28(2):114-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics.
  • The histopathologic distinction of cervical adenocarcinoma in situ (AIS) and invasive adenocarcinoma (AC) from some benign endocervical lesions can be challenging.
  • In this immunohistochemical study the utility of the ProEx C reagent in distinguishing AIS and AC from a variety of non-neoplastic glandular lesions was examined.
  • ProEx C immunohistochemical staining was performed on sections from formalin-fixed, paraffin-embedded tissue of 65 cervical tissues including 48 non-neoplastic cervices (normal [n=10], microglandular hyperplasia [n=10], tubal metaplasia [n=11], cervical endometriosis [n=7], reactive endocervix [n=10]) and 17 cervices with glandular malignancy (AIS [n=12] and AC [n=5]).
  • The median and distribution of scores for both prevalence and intensity was compared for AIS versus each of the 5 benign cervical lesions using a Mann-Whitney U test.
  • The median and distribution of prevalence of immunohistochemical staining for AIS was different from all benign mimics, but the intensity of staining for AIS did overlap with some mimics as it was not significantly different from endometriosis, microglandular hyperplasia, and reactive endocervix.
  • ProEx C reagent has potential as an adjunctive testing tool in the histopathologic diagnosis of both AIS and AC, particularly in difficult cases with small biopsies or foci of disease.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, Neoplasm / biosynthesis. Cell Cycle Proteins / biosynthesis. Cervical Intraepithelial Neoplasia / diagnosis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Immunohistochemistry / methods. Nuclear Proteins / biosynthesis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / metabolism. Minichromosome Maintenance Complex Component 2. Pilot Projects. Reagent Kits, Diagnostic

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19188825.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Reagent Kits, Diagnostic; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


34. Sharpless KE, Schnatz PF, Mandavilli S, Greene JF, Sorosky JI: Dysplasia associated with atypical glandular cells on cervical cytology. Obstet Gynecol; 2005 Mar;105(3):494-500
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysplasia associated with atypical glandular cells on cervical cytology.
  • Most women aged younger than 35 years had a squamous abnormality, whereas women aged 35 years or older had a greater diversity of squamous and glandular lesions and accounted for all cases of endometrial cancer, adenocarcinoma in situ, and cervical adenocarcinoma.
  • [MeSH-major] Cervix Uteri / pathology. Uterine Cervical Dysplasia / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / pathology. Female. Humans. Middle Aged. Uterine Cervical Neoplasms / pathology. Vaginal Smears

  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Obstet Gynecol. 2005 Jun;105(6):1495
  • (PMID = 15738014.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. McCluggage WG, Hurrell DP, Kennedy K: Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases. Am J Surg Pathol; 2010 May;34(5):735-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases.
  • Metastatic tumors within the cervix are uncommon if one excludes endometrial carcinoma, which involves the cervix by direct spread.
  • A variety of other neoplasms rarely metastasize to the cervix and, in most cases, the diagnosis is straightforward because of a combination of clinical and pathologic parameters, common features of metastatic carcinoma within the cervix including predominant involvement of the deep stroma, absence of surface involvement and of an in situ component, and prominent lymphovascular permeation.
  • We describe 6 cases of metastatic adenocarcinoma involving the cervix with superficial "mucosal" involvement mimicking primary cervical adenocarcinoma or adenocarcinoma in situ.
  • In 5 cases, the primary adenocarcinoma was in the ovary or peritoneum and was of serous (4 cases) or clear-cell (1 case) type.
  • In the other case, the primary neoplasm was in the pancreas and this was initially interpreted as a primary cervical adenocarcinoma.
  • In the cases of primary ovarian or peritoneal carcinoma, the mucosal tumor within the cervix, which was discovered at the same time as the ovarian or peritoneal neoplasm, raised the possibility of synchronous independent lesions or metastasis from the cervix to the ovary or peritoneum.
  • Positive staining for WT1, p53, and estrogen receptor in the cases of serous carcinoma and an absence of human papillomavirus by linear array genotyping in all cases was of value in excluding a primary cervical neoplasm, although these ancillary studies are supplementary to microscopic examination.
  • In those cases with an ovarian or peritoneal primary, the likely pathogenesis of the cervical involvement is transtubal and intrauterine spread.
  • It is important for the pathologist to be aware of the possibility of cervical mucosal metastasis to avoid an erroneous diagnosis of a primary cervical adenocarcinoma or adenocarcinoma in situ.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Cystadenocarcinoma, Serous / diagnosis. Ovarian Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Middle Aged


36. Rabban JT, McAlhany S, Lerwill MF, Grenert JP, Zaloudek CJ: PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma. Am J Surg Pathol; 2010 Feb;34(2):137-46
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma.
  • Mesonephric remnants of the cervix are vestiges of the embryonic mesonephric system which typically regresses during female development.
  • The differential diagnosis of exuberant mesonephric hyperplasia includes minimal deviation adenocarcinoma of the cervix, a tumor with deceptively bland morphology for which no reliable diagnostic biomarkers currently exist.
  • We hypothesized that PAX2 may also be expressed in mesonephric lesions of the cervix and may distinguish mesonephric hyperplasia from minimal deviation adenocarcinoma of the cervix.
  • We demonstrated that PAX2 was strongly and diffusely expressed in mesonephric remnants (6 of 6) and in mesonephric hyperplasia (18 of 18); however, no expression was noted in mesonephric adenocarcinoma (0 of 1).
  • PAX2 was expressed in normal endocervical glands (including tunnel clusters and Nabothian cysts) (86 of 86), lobular endocervical glandular hyperplasia (5 of 5), tubal/tuboendometrioid metaplasia (8 of 8), and cervical endometriosis (13 of 14).
  • In contrast, only 2 cases of endocervical adenocarcinoma were positive for PAX2 [invasive adenocarcinoma of the minimal deviation type (0 of 5), usual type (1 of 22), and endometrioid type (1 of 1)].
  • Adjacent adenocarcinoma in situ, as well as cases of pure adenocarcinoma in situ (0 of 6), were also PAX2 negative.
  • These results suggest that PAX2 immunoreactivity may be useful to (1) distinguish mesonephric hyperplasia from minimal deviation adenocarcinoma, (2) to distinguish lobular endocervical glandular hyperplasia from minimal deviation adenocarcinoma, and (3) to distinguish endocervical tubal metaplasia or cervical endometriosis from endocervical adenocarcinoma in situ.
  • Overall, a strong, diffuse nuclear PAX2 expression pattern in a cervical glandular proliferation predicts a benign diagnosis (positive predictive value 90%, negative predictive value 98%; P<0.001); however, PAX2 should not be interpreted in isolation from the architectural and cytologic features of the lesion as it may be expressed in some stage II endometrial adenocarcinomas involving the cervix.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Cervix Uteri / pathology. Mesonephros / pathology. Mullerian Ducts / pathology. PAX2 Transcription Factor / metabolism. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor. Cell Nucleus / metabolism. Cell Nucleus / pathology. Diagnosis, Differential. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / metabolism. Immunohistochemistry / methods. Neoplasm Staging. Precancerous Conditions / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20061933.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human
  •  go-up   go-down


37. Altaf FJ: Cervical cancer screening with pattern of pap smear. Review of multicenter studies. Saudi Med J; 2006 Oct;27(10):1498-502
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical cancer screening with pattern of pap smear. Review of multicenter studies.
  • OBJECTIVE: To estimate the frequency of abnormal cervical smears and to compare the findings with earlier reported data from Saudi Arabia.
  • The malignant categories were squamous cell carcinoma (0.08%), adenocarcinoma of cervix in situ (0.02%) and invasive (0.04%).
  • Unified national programs for diagnosing cervical precancerous lesions should be established covering different region of the Kingdom to evaluate the magnitude of the problem.
  • [MeSH-major] Papanicolaou Test. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / epidemiology. Vaginal Smears / trends


38. Sláma J, Freitag P, Cibula D, Fischerová D, Janousek M, Pavlista D, Strunová M, Zikán M, Jancárková N: [Glandular premalignant lesions of the uterine cervix]. Ceska Gynekol; 2006 Dec;71(6):446-50
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Glandular premalignant lesions of the uterine cervix].
  • OBJECTIVE: Review of diagnostical and therapeutical methods in glandular premalignant lesions of the uterine cervix.
  • RESULTS: The incidence of invasive adenocarcinomas of the uterine cervix is increasing.
  • PAP-smear of AGC-NOS/-NEO or adenocarcinoma in situ (AIS) in combination with typical colposcopic appearance raise a suspicion of glandular lesion.
  • Direct biopsy must be always performed to get definite diagnosis.
  • CONCLUSION: Diagnosis of glandular premalignat lesion of the uterine cervix is more complicated in comparison to spinocellular one, however it is getting more significant due to increasing incidence.


39. Swartz RJ, West LA, Boiko I, Malpica A, Guillaud M, Macaulay C, Follen M, Atkinson EN, Cox DD: Classification using the cumulative log-odds in the quantitative pathologic diagnosis of adenocarcinoma of the cervix. Gynecol Oncol; 2005 Dec;99(3 Suppl 1):S24-31
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classification using the cumulative log-odds in the quantitative pathologic diagnosis of adenocarcinoma of the cervix.
  • The method was tested using data from cervical adenocarcinomas, adenocarcinoma in situ, and normal columnar tissue.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Logistic Models. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology


40. Biscotti CV, Ray N: Papanicolaou tests associated with cervical mucosal endometriosis: an analysis of cellular features and comparison to endocervical adenocarcinoma in situ. Diagn Cytopathol; 2010 Aug;38(8):551-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papanicolaou tests associated with cervical mucosal endometriosis: an analysis of cellular features and comparison to endocervical adenocarcinoma in situ.
  • Endometrium directly sampled from endocervical mucosal endometriosis can mimic endocervical adenocarcinoma in situ (AIS) in Papanicolaou (Pap) tests.
  • We analyzed a series of Pap tests to investigate the cellular features of mucosal endometriosis and to assess the utility of stroma and apoptotic bodies in the differential diagnosis with AIS.
  • Pap test samples from patients known to have endocervical mucosal endometriosis were compared with samples containing AIS.
  • By comparison, only one (8%) AIS case had endometrial-type stroma.
  • Seven (58%) AIS cases had apoptotic bodies and three (25%) had mitotic figures.
  • These lesional cells almost always include stroma, which is useful in the differential diagnosis with AIS.
  • We identified stroma significantly more often in endometriosis cases (92%) than in AIS cases (8%).
  • In the absence of stroma, AIS should be considered.
  • [MeSH-major] Carcinoma in Situ / pathology. Cervix Uteri / pathology. Endometriosis / pathology. Mucous Membrane / pathology. Papanicolaou Test. Uterine Cervical Neoplasms / pathology. Vaginal Smears / methods


41. Dunton CJ: Management of atypical glandular cells and adenocarcinoma in situ. Obstet Gynecol Clin North Am; 2008 Dec;35(4):623-32; ix
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for adenocarcinoma in situ .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of atypical glandular cells and adenocarcinoma in situ.
  • Glandular abnormalities of the cervix remain a difficult clinical problem.
  • It also discusses the diagnosis of associated endometrial lesions and the use of human papillomavirus DNA testing in the management of glandular lesions of the lower genital tract.
  • [MeSH-major] Adenocarcinoma / therapy. Cervical Intraepithelial Neoplasia / therapy. Pregnancy Complications, Neoplastic / therapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy. Cervix Uteri / cytology. Cervix Uteri / pathology. DNA, Viral / analysis. Female. Humans. Middle Aged. Papillomaviridae / isolation & purification. Papillomavirus Infections / complications. Papillomavirus Infections / pathology. Papillomavirus Infections / therapy. Postmenopause. Pregnancy. Vaginal Smears. Young Adult


42. Liang J, Mittal KR, Wei JJ, Yee H, Chiriboga L, Shukla P: Utility of p16INK4a, CEA, Ki67, P53 and ER/PR in the differential diagnosis of benign, premalignant, and malignant glandular lesions of the uterine cervix and their relationship with Silverberg scoring system for endocervical glandular lesions. Int J Gynecol Pathol; 2007 Jan;26(1):71-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of p16INK4a, CEA, Ki67, P53 and ER/PR in the differential diagnosis of benign, premalignant, and malignant glandular lesions of the uterine cervix and their relationship with Silverberg scoring system for endocervical glandular lesions.
  • Early detection of premalignant and malignant glandular lesions of the uterine cervix and their distinction from benign mimics is crucial but sometimes difficult.
  • In this study, we investigated utility of expression of p16, CEA, Ki67, p53 and ER/PR in evaluating the benign, premalignant, and malignant glandular lesions of the uterine cervix.
  • A total of 35 cervical cone or LEEP cases were collected including 14 adenocarcinoma in situ (AIS), 7 endocervical glandular dysplasia (EGD), and 14 benign mimics (BM).
  • The histological scores assigned independently by 4 pathologists were all equal or above 6 for AIS, between 3 and 5 for EGD, and equal or below 3 for BM.
  • There was increased expression of p16 and CEA in EGD compared with BM (P < 0.05), with further increase in expression of these markers in AIS compared with EGD (P < 0.05).
  • Ki67 expression was significantly increased in AIS compared to EGD (P < 0.05) as well as compared to BM (P < 0.05).
  • There was a loss of ER/PR in cervical AIS, but not in EGD.
  • Our results indicate that the Silverberg scoring system is a useful tool in differential diagnosis of cervical glandular lesions for increased diagnostic accuracy and interobserver agreement.
  • Most cervical glandular lesions can be differentiated by using a combination of histological scores with a panel of immunomarkers.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Precancerous Conditions / diagnosis. Precancerous Conditions / metabolism. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Carcinoembryonic Antigen / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Diagnosis, Differential. Female. Humans. Ki-67 Antigen / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Tumor Suppressor Protein p53 / metabolism


43. Nara M, Hashi A, Murata S, Kondo T, Yuminamochi T, Nakazawa K, Katoh R, Hoshi K: Lobular endocervical glandular hyperplasia as a presumed precursor of cervical adenocarcinoma independent of human papillomavirus infection. Gynecol Oncol; 2007 Aug;106(2):289-98
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lobular endocervical glandular hyperplasia as a presumed precursor of cervical adenocarcinoma independent of human papillomavirus infection.
  • OBJECTIVES: The aim of this study was to investigate differences in the process of carcinogenesis between adenocarcinoma coexistent with LEGH and conventional adenocarcinoma.
  • METHODS: Using the surgical pathology files of patients who visited the University of Yamanashi Hospital, Yamanashi Central Hospital and Kofu Municipal Hospital between 1996 and 2005, pathological diagnoses were reevaluated based on criteria for the diagnosis of LEGH by Nucci et al.
  • As for the cases including adenocarcinoma with LEGH: (a) we created a map showing position of the LEGH component and adenocarcinoma component and squamo-columnar junction (SCJ) in HE-stained specimens, (b) immunohistochemical staining was performed using antibodies to CEA, HIK1083 and p53, and (c) detection of HPV DNA was performed using PCR and in situ hybridization (ISH).
  • RESULTS: Endocervical adenocarcinoma was observed coexistent with LEGH in 5 cases (19.2%). (a) LEGH was located in a remote place from the SCJ.
  • Sizes of lesions in the 5 cases ranged from 18 to 35 mm in width and 7 to 16 mm in depth. (b) HIK1083 was diffusely immunopositive in the cytoplasm of LEGH component and focal immunopositive in 4 cases with adenocarcinoma component.
  • Immunopositivity for CEA was seen in the cytoplasm of adenocarcinoma component in 4 cases.
  • Immunopositivity for p53 was seen in adenocarcinoma component nuclei in 2 cases. (c) HPV DNA was not detected using PCR and ISH in either LEGH or adenocarcinoma components.
  • CONCLUSIONS: The present study suggests that clear differences exist in the process of carcinogenesis between adenocarcinoma associated with LEGH and conventional adenocarcinoma.
  • LEGH may represent a precursor of cervical adenocarcinoma independent of HPV infection.
  • As LEGH displays characteristics of precancerous mucinous adenocarcinoma, surgical treatment should be considered for LEGH growing beyond a certain size.
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Neoplasms, Glandular and Epithelial / pathology. Precancerous Conditions / pathology. Uterine Cervical Neoplasms / pathology


44. Wheeler DT, Kurman RJ: The relationship of glands to thick-wall blood vessels as a marker of invasion in endocervical adenocarcinoma. Int J Gynecol Pathol; 2005 Apr;24(2):125-30
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship of glands to thick-wall blood vessels as a marker of invasion in endocervical adenocarcinoma.
  • Routinely stained slides were examined from 50 invasive endocervical adenocarcinomas (37 of usual type and 13 of minimal deviation type), 26 noninvasive lesions (14 cases of adenocarcinoma in situ, 7 cases of hyperplasia, 4 cases of tunnel clusters, 1 adenomyoma), and 20 normal cervices, including 7 with deep nabothian cysts.
  • In conclusion, close proximity of glands to thick-wall blood vessels (distance from the closest gland to a thick-wall vessel less than or equal to the thickness of the vessel wall) seems to be a useful feature in the diagnosis of invasive endocervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor. Cervix Uteri / blood supply. Neoplasm Invasiveness / diagnosis. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Predictive Value of Tests. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15782068.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


45. Fujii T, Nakamura M, Kameyama K, Saito M, Nishio H, Ohno A, Hirao N, Iwata T, Tsukazaki K, Aoki D: Digital colposcopy for the diagnosis of cervical adenocarcinoma using a narrow band imaging system. Int J Gynecol Cancer; 2010 May;20(4):605-10
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Digital colposcopy for the diagnosis of cervical adenocarcinoma using a narrow band imaging system.
  • INTRODUCTION: Although the colposcopic features of cervical glandular disease and cervical adenocarcinoma are not widely well known, unique microvascular patterns are reportedly useful for identifying such diseases.
  • METHODS: Twenty-one patients with adenocarcinoma in situ or early invasive adenocarcinomas were examined using digital NBI colposcopy, and the photo records were compared with those of conventional colposcopy.
  • RESULTS: Digital NBI colposcopy depicted the fine vascular texture on the surface of the cervix more clearly than conventional colposcopy.
  • The characteristic fine vascular patterns were critical for identifying cervical glandular diseases.
  • CONCLUSIONS: Digital NBI colposcopy was useful for identifying early cervical adenocarcinoma as well as adenocarcinoma in situ.
  • This system yields cervical glandular disease-related colposcopic findings that may be useful for both clinical and educational purposes.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Adenosquamous / diagnosis. Colposcopy. Diagnostic Imaging. Uterine Cervical Neoplasms / diagnosis


46. Negri G, Romano F, Vittadello F, Kasal A, Mazzoleni G, Colombetti V, Egarter-Vigl E: Laminin-5 gamma2 chain immunohistochemistry facilitates the assessment of invasiveness and improves the diagnostic reproducibility of glandular lesions of the cervix uteri. Hum Pathol; 2006 Jun;37(6):704-10
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laminin-5 gamma2 chain immunohistochemistry facilitates the assessment of invasiveness and improves the diagnostic reproducibility of glandular lesions of the cervix uteri.
  • The aim of this study was to evaluate the influence of laminin-5 (LN-5) gamma2 chain immunohistochemistry on the assessment of invasiveness in cervical adenocarcinomas and its impact on the diagnostic reproducibility of glandular lesions of the cervix uteri.
  • Immunohistochemistry with LN-5 gamma2 was performed on 30 cases, including 12 adenocarcinomas in situ (AISs), 5 AISs that were suggestive, albeit not conclusive, of infiltration (AIS+), 7 frankly invasive adenocarcinomas, and 6 nonneoplastic cases with reactive changes.
  • Laminin-5 gamma2 was expressed in 5 of the 12 AISs (41.6%), all AIS+ and invasive adenocarcinomas, and none of the reactive cases.
  • The difference in interobserver agreement further increased when including only AISs and AIS+ in the analysis (0.17 versus 0.72; P = .000).
  • After immunohistochemical evaluation, the original AIS diagnosis was unanimously changed to adenocarcinoma with minimal stromal invasion in 3 of 12 cases (25%), whereas a discordant hematoxylin-eosin diagnosis turned into a concordant one in 10 of 13 cases (6 AISs, 2 AIS+, 2 adenocarcinomas; 76.9%).
  • Immunohistochemistry with LN-5 gamma2 facilitates the assessment of the invasiveness of cervical adenocarcinomas and improves the interobserver agreement in glandular lesions of the cervix uteri.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cell Adhesion Molecules / analysis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology


47. Vang R, Vinh TN, Burks RT, Barner R, Kurman RJ, Ronnett BM: Pseudoinfiltrative tubal metaplasia of the endocervix: a potential form of in utero diethylstilbestrol exposure-related adenosis simulating minimal deviation adenocarcinoma. Int J Gynecol Pathol; 2005 Oct;24(4):391-8
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudoinfiltrative tubal metaplasia of the endocervix: a potential form of in utero diethylstilbestrol exposure-related adenosis simulating minimal deviation adenocarcinoma.
  • We report three cases of unusual tubal-type endocervical glandular proliferations simulating minimal deviation adenocarcinoma in women with a history of in utero diethylstilbestrol (DES) exposure.
  • Human papillomavirus DNA was not detected by in situ hybridization in one case that was tested.
  • The proliferations lacked features of mucinous and tubo-endometrioid types of minimal deviation adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Cervix Uteri / pathology. Diethylstilbestrol / adverse effects. Uterine Cervical Neoplasms
  • [MeSH-minor] Adult. Cell Nucleus / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Metaplasia. Middle Aged. Mitosis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16175088.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


48. Kalir T, Simsir A, Demopoulos HB, Demopoulos RI: Obstacles to the early detection of endocervical adenocarcinoma. Int J Gynecol Pathol; 2005 Oct;24(4):399-403
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obstacles to the early detection of endocervical adenocarcinoma.
  • We observed that the ratio of in situ to invasive carcinomas of the cervix is significantly greater for squamous than for glandular lesions.
  • We wondered whether Pap smears were less effective for the identification of in situ glandular lesions.
  • Ten patients had in situ disease, seven (70%) of which involved the transformation zone (TZ); all seven of these were identified by Pap smears.
  • Among the 23 patients with invasive disease that spared the TZ, 6 (26%) had a documented history of negative Pap smears at New York University within 3 years of diagnosis.
  • Noteworthy was the finding that two of these six lesions extended from the endocervix upward, through the stroma, and into the endomyometrium of the lower uterine segment.
  • [MeSH-major] Adenocarcinoma / diagnosis. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16175089.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


49. Tsuda H, Mikami Y, Kaku T, Hasegawa T, Akiyama F, Ohishi Y, Sasajima Y, Kasamatsu T: Reproducible and clinically meaningful differential diagnosis is possible between lobular endocervical glandular hyperplasia and 'adenoma malignum' based on common histopathological criteria. Pathol Int; 2005 Jul;55(7):412-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reproducible and clinically meaningful differential diagnosis is possible between lobular endocervical glandular hyperplasia and 'adenoma malignum' based on common histopathological criteria.
  • The aim of the present study was to determine if the differential diagnosis between lobular endocervical glandular hyperplasia (LEGH) and minimal deviation adenocarcinoma (MDA), or 'adenoma malignum', is reproducible when clear criteria for these two lesions are given.
  • A total of 44 proliferative endocervical glandular lesions were collected, for which differential diagnosis from MDA was considered to be necessary.
  • Seven observers independently classified these 44 lesions into LEGH, LEGH with adenocarcinoma in situ (AIS), MDA, or common cervical adenocarcinoma, according to the following criteria: LEGH was non-invasive proliferation of endocervical glandular cells without any obvious adenocarcinoma component.
  • MDA was very well-differentiated endocervical-type mucinous adenocarcinoma composed mostly of LEGH-looking glands but containing the component of obviously invasive adenocarcinoma.
  • LEGH with AIS was defined as continuous coexistence of LEGH and AIS.
  • The level increased to almost perfect (kappa = 0.928) between the group of non-invasive lesions consisting of LEGH and LEGH with AIS and the other group of invasive lesions comprising MDA and common adenocarcinoma.
  • When the modal diagnosis was adopted as the final diagnosis for individual lesions, the 5 year survival rate of patients after surgery was 100% for the non-invasive lesions but only 54% for the invasive lesions (P < 0.01).
  • It is clearly shown that reproducible differential diagnosis is possible between LEGH, LEGH with AIS, and MDA and that such a differentiation is clinically meaningful.
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Histocytochemistry / methods. Humans. Hyperplasia. Prognosis. Reproducibility of Results. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982216.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


50. O'Neill CJ, McCluggage WG: p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol; 2006 Jan;13(1):8-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16 expression in the female genital tract and its value in diagnosis.
  • Diffuse (as opposed to focal) positivity with p16 in the cervix can be regarded as a surrogate marker of the presence of high-risk human papillomavirus (HPV).
  • In cervical squamous lesions, p16 is positive in most high-grade cervical intraepithelial neoplasia (CIN) and in some cases of low-grade CIN, usually those associated with high-risk HPV. p16 may be useful to identify small focal high-grade CIN lesions, to distinguish some cases of CIN involving immature metaplastic squamous epithelium from immature metaplastic squamous epithelium not involved by CIN and to distinguish high-grade CIN from benign mimics.
  • Most cervical carcinomas of squamous, glandular, and small cell type are p16-positive.
  • In cervical glandular lesions, p16 is useful, as part of a panel, in the distinction between adenocarcinoma in situ (diffusely positive) and benign mimics, including tuboendometrial metaplasia and endometriosis, which are usually p16-negative or focally positive. p16 may be used, in combination with other markers, to distinguish between a cervical adenocarcinoma (diffuse positivity) and an endometrioid-type endometrial adenocarcinoma (negative or focally positive).
  • Some uterine serous carcinomas are diffusely positive.
  • In the uterus, p16 positivity is more common and widespread in leiomyosarcomas than leiomyomas, and this may be a useful aid to diagnosis, although problematic uterine smooth muscle neoplasms have not been extensively studied.
  • Metastatic cervical adenocarcinomas in the ovary are usually diffusely p16-positive, and because these may closely mimic a primary ovarian endometrioid or mucinous adenocarcinoma, this may be a valuable diagnostic aid, although p16 expression in primary ovarian adenocarcinomas of these morphologic subtypes has not been widely investigated.
  • Some ovarian serous carcinomas, similar to their uterine counterparts, are p16-positive.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / analysis. Genital Neoplasms, Female / diagnosis
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Carcinoma, Small Cell / chemistry. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / genetics. Cystadenocarcinoma, Serous / chemistry. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / genetics. Diagnosis, Differential. Endometrial Neoplasms / chemistry. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / genetics. Female. Genes, p16. Genitalia, Female / chemistry. Genitalia, Female / physiopathology. Humans. Immunohistochemistry. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / genetics. Tumor Suppressor Proteins / analysis. Tumor Suppressor Proteins / genetics. Uterine Cervical Neoplasms / chemistry. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / genetics. Uterine Neoplasms / chemistry. Uterine Neoplasms / diagnosis. Uterine Neoplasms / genetics. Vulvar Neoplasms / chemistry. Vulvar Neoplasms / classification. Vulvar Neoplasms / diagnosis. Vulvar Neoplasms / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462152.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Proteins
  • [Number-of-references] 65
  •  go-up   go-down


51. Salani R, Puri I, Bristow RE: Adenocarcinoma in situ of the uterine cervix: a metaanalysis of 1278 patients evaluating the predictive value of conization margin status. Am J Obstet Gynecol; 2009 Feb;200(2):182.e1-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in situ of the uterine cervix: a metaanalysis of 1278 patients evaluating the predictive value of conization margin status.
  • OBJECTIVE: We sought to determine the value of conization margin status in predicting residual and recurrent adenocarcinoma in situ (ACIS) of the cervix.
  • Invasive adenocarcinoma was more commonly associated with positive margins (5.2%) compared with negative margins (0.1%).
  • CONCLUSION: After conization for ACIS, patients with positive margins are significantly more likely to have residual or recurrent disease, whereas those with negative margins may be treated conservatively.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma in Situ / pathology. Conization. Neoplasm Recurrence, Local / epidemiology. Neoplasm, Residual / epidemiology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Cervix Uteri / pathology. Female. Humans. Predictive Value of Tests. Reoperation

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19019325.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  •  go-up   go-down


52. Confortini M, Di Bonito L, Carozzi F, Ghiringhello B, Montanari G, Parisio F, Prandi S, GISCi Working Group for Cervical Cytology: Interlaboratory reproducibility of atypical glandular cells of undetermined significance: a national survey. Cytopathology; 2006 Dec;17(6):353-60
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A set of 35 selected slides were circulated among 167 laboratories involved in local population-based cervical screening programmes.
  • Each laboratory provided one single diagnosis per smear.
  • The smears were read blind to the original diagnosis and to the diagnoses provided by other laboratories.
  • A 'majority' diagnosis was defined for each case and assumed as the reference standard.
  • The diagnosis provided from each laboratory was compared with the majority diagnosis.
  • RESULTS: According to the majority report the 35 slides in the set were classified as negative in nine cases, AGC in eight, adenocarcinoma in eight, and squamous lesion or squamous + glandular lesion in 10.
  • K-values were 0.46, 0.21, 0.34, 0.36 and 0.32 for negative, AGC/AIS (adenocarcinoma in situ of endocervix), AdenoCa, Sq/Sq + Gl and all reporting categories respectively.
  • The data confirmed the importance, in a screening scenario, of AGC/AIS diagnoses, but also presented difficulties in differentiating between the two diagnoses.
  • In addition to the results obtained from the circulation of the slides, laboratories which had annually a low number of cervical smears were able to gain experience focused on particular morphological pictures.
  • [MeSH-major] Cervix Uteri / cytology. Mass Screening / methods. Vaginal Smears / methods
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Female. Humans. Reproducibility of Results. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology


53. Schnatz PF, Guile M, O'Sullivan DM, Sorosky JI: Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol; 2006 Mar;107(3):701-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of atypical glandular cells on cervical cytology.
  • These data showed the following rates of pathology: 8.5% low-grade squamous intraepithelial lesions (LSIL), 11.1% high-grade squamous intraepithelial lesions (HSIL), 2.9% adenocarcinoma in situ, 1.4% endometrial hyperplasia, and 5.2% malignancy.
  • The most common malignancies were endometrial adenocarcinoma (57.6%), cervical adenocarcinoma (23.6%), ovarian and fallopian tube carcinoma (6.4%), squamous cell carcinoma of the cervix (5.4%), and other (6.9%).
  • CONCLUSION: Histologic diagnosis showed that 29.0% of these Pap tests had findings requiring follow-up or therapeutic intervention, including a 5.2% rate of malignancy.
  • [MeSH-major] Adenocarcinoma / pathology. Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / pathology. Endometrial Hyperplasia / pathology. Uterine Cervical Neoplasms / pathology


54. Liao SY, Rodgers WH, Kauderer J, Bonfiglio TA, Walker JL, Darcy KM, Carter R, Hatae M, Levine L, Spirtos NM, Stanbridge EJ: Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States. Int J Cancer; 2009 Nov 15;125(10):2434-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States.
  • High-risk human papillomavirus (H-HPV) infection is strongly linked to cervical neoplasia, but its role in detecting glandular lesions (GLs) is unclear.
  • In the cervix, carbonic anhydrase IX (CA-IX) is expressed in cervical neoplasia, but rarely in the benign cervix.
  • The diagnostic utility of these biomarkers was evaluated in women with a cytologic diagnosis of atypical glandular cells (AGC).
  • Of 403 patients, 111 (28%) were positive for significant cervical lesions (SCLs) including CIN2, CIN3, adenocarcinoma in situ or invasive carcinoma.
  • The combination of CA-IX with H-HPV testing does not improve the diagnostic accuracy for cervical neoplasia in women with AGC diagnosis over that of H-HPV testing alone.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Jul;30(7):816-25 [10414501.001]
  • [Cites] Am J Obstet Gynecol. 1998 Aug;179(2):382-90 [9731842.001]
  • [Cites] Diagn Cytopathol. 2006 Mar;34(3):235-9 [16470857.001]
  • [Cites] Am J Obstet Gynecol. 2005 Aug;193(2):559-65; discussion 565-7 [16098895.001]
  • [Cites] Vaccine. 2008 Aug 19;26 Suppl 10:K1-16 [18847553.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):1007-13 [16803477.001]
  • [Cites] J Clin Microbiol. 2006 Nov;44(11):3915-7 [16971652.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):1108-21 [10699902.001]
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):97-105 [10926787.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1055-62 [11021808.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):905-19 [11238039.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3660-8 [11504747.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6394-9 [11522632.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):222-7 [11668502.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):96-102 [11789738.001]
  • [Cites] Cancer. 2002 Feb 25;96(1):1-4 [11836696.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2114-9 [11966386.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2120-9 [11966387.001]
  • [Cites] Diagn Cytopathol. 2003 Nov;29(5):271-9 [14595795.001]
  • [Cites] Am J Clin Pathol. 2004 Jan;121(1):87-92 [14750245.001]
  • [Cites] Gynecol Oncol. 1989 Oct;35(1):1-7 [2792895.001]
  • [Cites] Acta Cytol. 1993 Mar-Apr;37(2):115-24 [8465628.001]
  • [Cites] Int J Cancer. 1993 May 8;54(2):268-74 [8486430.001]
  • [Cites] Am J Pathol. 1994 Sep;145(3):598-609 [8080042.001]
  • [Cites] Oncogene. 1994 Oct;9(10):2877-88 [8084592.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jul;5(7):549-57 [8827360.001]
  • [Cites] Gynecol Oncol. 1996 Oct;63(1):14-8 [8898161.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2827-31 [9230182.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1248-54 [18483347.001]
  • (PMID = 19670419.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA037517-25; United States / NCI NIH HHS / CA / CA027469-29; United States / NCI NIH HHS / CA / CA 11479; United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / U10 CA037517; None / None / / U10 CA037517-25; United States / NCI NIH HHS / CA / CA 37517; United States / NCI NIH HHS / CA / U10 CA027469-29
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Viral; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  • [Other-IDs] NLM/ NIHMS137629; NLM/ PMC2779726
  •  go-up   go-down


55. Kondo T, Hashi A, Murata S, Nakazawa T, Yuminamochi T, Nara M, Hoshi K, Katoh R: Endocervical adenocarcinomas associated with lobular endocervical glandular hyperplasia: a report of four cases with histochemical and immunohistochemical analyses. Mod Pathol; 2005 Sep;18(9):1199-210
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report on four cases of endocervical adenocarcinoma associated with lobular endocervical glandular hyperplasia using histochemical and immunohistochemical analyses.
  • Cytological examinations of the cervical smears revealed adenocarcinoma cells and benign-looking glandular cells with intracytoplasmic golden-yellow mucin in all cases.
  • From surgical specimens, three tumors were diagnosed as mucinous adenocarcinoma and one was adenocarcinoma in situ.
  • All adenocarcinomas were located proximally on the cervix, and did not involve the transformation zone.
  • Adjacent to carcinoma tissues in the cervix, lobular endocervical glandular hyperplasia was detected.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / pathology. Hyperplasia / complications. Hyperplasia / pathology. Uterine Cervical Neoplasms / complications. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Humans. Immunohistochemistry. Middle Aged. Mucins / metabolism. Precancerous Conditions / metabolism. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15761489.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


56. Lindeque BG: Management of cervical premalignant lesions. Best Pract Res Clin Obstet Gynaecol; 2005 Aug;19(4):545-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of cervical premalignant lesions.
  • Management of cervical preneoplasia starts with an abnormal smear result.
  • While patients with ASCUS can be followed with cytology or colposcopy, the risk of having cervical intra-epithelial neoplasia (CIN) is higher in patients with ASCH.
  • Such patients, as well as those with low-grade squamous intra-epithelial lesions on cytology, should be referred for colposcopy to ensure that diagnosis and treatment in CIN is detected.
  • Conservative excisional management of adenocarcinoma in situ by LLETZ or cold knife cone biopsy is not reported to be as effective as that of CIN, with high risk of residual and recurrent disease at follow-up.
  • The ability to detect and treat premalignant lesions on the cervix reversed the natural history of cervical cancer.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / surgery. Uterine Cervical Dysplasia / surgery. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Biopsy / methods. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Carcinoma, Squamous Cell / pathology. Cervix Uteri / pathology. Colposcopy / methods. Female. HIV Infections / complications. Humans. Hysterectomy / methods. Laser Therapy / methods. Neoplasm Recurrence, Local / pathology. Postoperative Complications. Pregnancy. Vaginal Smears / methods


57. Connolly TP, Evans AC: Atypical Papanicolaou smear in pregnancy. Clin Med Res; 2005 Feb;3(1):13-8
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Atypical glandular cells (AGC) in Papanicolaou (Pap) smears can be associated with premalignant and malignant cervical and endometrial lesions.
  • Positive diagnosis of endocervical adenocarcinoma in situ resulted in a risk-informed decision to proceed with a cold knife conization of the cervix.
  • Final pathology showed complete resection of the lesion with negative margins and an additional area of squamous dysplasia (cervical intraepithelial neoplasia, grade II to III).
  • [MeSH-major] Carcinoma in Situ / diagnosis. Cervix Uteri / pathology. Papanicolaou Test. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears
  • [MeSH-minor] Adult. Biopsy. Cervical Intraepithelial Neoplasia / diagnosis. Female. Humans. Pregnancy. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / surgery


58. Smedts F, Ramaekers FC, Hopman AH: The two faces of cervical adenocarcinoma in situ. Int J Gynecol Pathol; 2010 Jul;29(4):378-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The two faces of cervical adenocarcinoma in situ.
  • In order of frequency, cervical intraepithelial neoplasia (CIN), combined adenocarcinoma in situ (AIS)/CIN lesions, and solitary AIS are the most prevalent premalignant lesions of the uterine cervix.
  • As the morphologic distinction of these subtypes is not always straightforward, we performed an immunophenotyping analysis to establish distinguishing profiles for each of these squamous and glandular progenitor lesions of cervical carcinoma.
  • A series of 26 premalignant cervical lesions, comprising 13 cases of AIS, of which 7 represented solitary AIS and 6 were combined with CIN (combined AIS/CIN), as well as 13 solitary high-grade CIN lesions, were immunophenotypically analyzed using antibodies directed against p16, p63, bcl-2, and cytokeratins (CK) 5, 7, 8, 13, 17, 18, and 19.
  • Combined AIS/CIN lesions also expressed the full complement of markers in both the AIS and CIN compartments.
  • However, the expression of p63, bcl-2, CK5, and CK17 was lower in AIS compared with CIN.
  • The solitary AIS lesions could be subdivided into 2 subgroups, 1 expressing the full complement of markers and a second group in which no expression of p63, bcl-2, CK5, and a sporadically CK17 expression was observed.
  • We conclude that 2 phenotypically distinct types of AIS can be identified, that is, AIS with a reserve cell marker phenotype and AIS with an endocervical glandular phenotype.
  • These observations support the view that reserve cells are capable of bidirectional premalignant transformation, that is, into CIN and reserve cell-type AIS, as well as combined AIS/CIN.
  • The endocervical type of AIS is probably a result of the unidirectional transformation of progenitor cells within the glandular cell compartment.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Cervical Intraepithelial Neoplasia / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20567153.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


59. Roberts JM, Thurloe JK, Biro C, Hyne SG, Williams KE, Bowditch RC: Follow-up of cytologic predictions of endocervical glandular abnormalities: histologic outcomes in 123 cases. J Low Genit Tract Dis; 2005 Apr;9(2):71-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: We obtained histologic follow-up for 100% of 67 cytologic predictions of adenocarcinoma in situ (AIS) and 82% of 39 predictions of possible AIS (?AIS) made over a 4-year period (1999-2002) and for 25% of 105 atypical endocervical cells (AEC) predictions over a 12-month period (2000).
  • RESULTS: PPVs for predictions of AIS and ?AIS for high-grade lesions overall were 91% and 75% (p = .032), respectively, and those for high-grade glandular lesions were 88% and 72% (p = .046), respectively.
  • CONCLUSION: Cytology can accurately predict AIS.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma in Situ / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cervix Uteri / pathology. Cytodiagnosis / methods. Cytodiagnosis / standards. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Retrospective Studies. Vaginal Smears


60. Vang R, Gown AM, Farinola M, Barry TS, Wheeler DT, Yemelyanova A, Seidman JD, Judson K, Ronnett BM: p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol; 2007 May;31(5):653-63
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The HPV status of the endocervical adenocarcinomas was determined by in situ hybridization and polymerase chain reaction (when in situ hybridization was negative).
  • Diffuse (>75% positive tumor cells) moderate to strong p16 expression is a sensitive (100%) and specific (97%) marker for identifying HPV-related endocervical adenocarcinomas metastatic to the ovary among the primary ovarian tumors and metastatic adenocarcinomas from other sites that are in the differential diagnosis of ovarian tumors having mucinous and/or endometrioid/endometrioidlike differentiation. p16 is useful as part of a panel of immunohistochemical markers for distinguishing primary ovarian tumors from metastases and, when diffusely positive, can suggest the cervix as a potential primary site for metastatic adenocarcinomas of unknown origin.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Carcinoma, Endometrioid / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Ovarian Neoplasms / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. DNA, Viral / analysis. Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Papillomaviridae / genetics. Papillomavirus Infections. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460447.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral
  •  go-up   go-down


61. Basic E, Kozaric H, Kozaric M, Suko A: Conization as treatment of choice for precancerous changes and university cervical cancer at the Department of Obstetrics and Gynecology of Clinical Center of Sarajevo University in 2009. Med Arh; 2010;64(3):171-4
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conization as treatment of choice for precancerous changes and university cervical cancer at the Department of Obstetrics and Gynecology of Clinical Center of Sarajevo University in 2009.
  • According to the Public Health Institute of the Federation of Bosnia and Herzegovina there were 132 newly diagnosed patients with cervical cancer in 2008.
  • AIM: The aim of this article is to present the incidence of precancerous changes on the cervix and cervical cancer as well as the incidence of the use of conization as the type of treatment for cervical patients.
  • RESULTS: In 2009 at the Clinic of Gynecology and Obstetrics there were 72 newly diagnosed women with cervical cancer, out of which 16 had in situ carcinoma, 158 CIN I lesions, 64 CIN II lesions, and 46 CIN III lesions.
  • Planocellular carcinoma was diagnosed in 59 patients (82%), cervical adenocarcinoma in 13 patients (18%).
  • The most common diagnosis made with pathohistological analysis of the conization was CIN III/CIS, which was found in 48 (29%) patients.
  • CONCLUSION: Surgical method of treatment of precancerous changes as well as cervical cancer using the cold-knife conization with Sturmdorf sutures has shown high efficacy but with certain disadvantages such as the formation of scars, cervical stenosis, postoperative bleeding and others.
  • [MeSH-major] Precancerous Conditions / surgery. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Cervical Intraepithelial Neoplasia / surgery. Conization. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Cervical cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20645513.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


62. de Oliveira ER, Derchain SF, Sarian LO, Rabelo-Santos SH, Gontijo RC, Yoshida A, Andrade LA, Zeferino LC: Prediction of high-grade cervical disease with human papillomavirus detection in women with glandular and squamous cytologic abnormalities. Int J Gynecol Cancer; 2006 May-Jun;16(3):1055-62
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of high-grade cervical disease with human papillomavirus detection in women with glandular and squamous cytologic abnormalities.
  • The objective of this study was to assess whether human papillomavirus (HPV) detection with hybrid capture II (HC II) can help predict the presence and the nature, glandular or squamous, of histologic cervical lesions in women referred due to atypical glandular cells (AGC) or high-grade squamous intraepithelial lesion (HSIL).
  • Referral Pap smears comprised AGC (51 cases), AGC plus HSIL (28 cases), adenocarcinoma in situ (10 cases), and HSIL (158 cases).
  • All patients were tested for high-risk HPV with HC II and had a histologic assessment of their cervix.
  • Almost 70% of AGC-HPV-negative patients did not have a pathologically proven cervical neoplasia, whereas 76% of women with AGC-HPV-positive result were diagnosed with a squamous or glandular neoplasia.
  • We conclude that in women with AGC, HPV positivity strongly correlated with the presence of glandular or squamous cervical lesion but did not help distinguishing women with squamous from those with glandular neoplasia.
  • [MeSH-major] Carcinoma, Squamous Cell / virology. Mass Screening / methods. Papillomaviridae / isolation & purification. Uterine Cervical Diseases / virology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Adult. Carcinoma in Situ / diagnosis. Carcinoma in Situ / epidemiology. Carcinoma in Situ / virology. Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / epidemiology. DNA Probes, HPV. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasms, Glandular and Epithelial / diagnosis. Neoplasms, Glandular and Epithelial / epidemiology. Neoplasms, Glandular and Epithelial / virology. Neoplasms, Squamous Cell / epidemiology. Neoplasms, Squamous Cell / virology. Precancerous Conditions / diagnosis. Precancerous Conditions / epidemiology. Precancerous Conditions / virology. Predictive Value of Tests. Uterine Cervical Dysplasia / diagnosis. Uterine Cervical Dysplasia / epidemiology. Uterine Cervical Dysplasia / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Cervix Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803485.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Probes, HPV
  •  go-up   go-down


63. Flannelly G: The management of women with abnormal cervical cytology in pregnancy. Best Pract Res Clin Obstet Gynaecol; 2010 Feb;24(1):51-60
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of women with abnormal cervical cytology in pregnancy.
  • The emphasis should be on diagnosis and confirmation of cervical precancer (Cervical intraepithelial neoplasia (CIN) or Adenocarcinoma in situ (AIS), thus excluding invasive cancer).
  • This must include colposcopy and take into account the physiological changes of the cervix during pregnancy and the puerperium.
  • The management of women with invasive cancer diagnosed during pregnancy depends on the gestation at diagnosis and requires careful assessment and multidisciplinary planning.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / surgery. Precancerous Conditions / surgery. Pregnancy Complications, Neoplastic / surgery. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Carcinoma in Situ / diagnosis. Carcinoma in Situ / surgery. Colposcopy. Evidence-Based Medicine. Female. Humans. Hysterectomy / methods. Pregnancy. Survival Analysis. Treatment Outcome. Vaginal Smears

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19805007.001).
  • [ISSN] 1532-1932
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


64. Ben Hmid R, Mourali M, Zghal D, Mahjoub S, Naceur C, Sbai N, Zouari F: [Usefulness of colposcopy in inflammatory cervico-vaginal smears: apropos of 140 cases]. Tunis Med; 2007 Jun;85(6):500-4
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Apport de la colposcopie dans les frottis cervico-vaginaux inflammatoires: a propos de 140 cas.
  • BACKGROUND: The cervical cancer is the second most frequent cancer of the woman in Tunisia.
  • AIM: The purpose of our study is to proove that an inflammatory cervical smear should be considered as a positive test and must lead to other investigations.
  • METHODS: It is a prospective study over 140 cases of inflammatory cervical smears (without atypical cells) diagnosed during a year period from june 2001 to june 2002.
  • It showed benign lesions such as: ectropion in 22.85%, colpitis in 14.28%, cervical polypus in 5%, normal transformation zone in 8.57%, but also suspicious lesions such as : atypical transformations grade I (ATGI) in 25.71% and atypical transformations grade II (ATGII) in 13.57%.
  • A case of in situ carcinoma, a microinvasif epidermoid carcinoma and an invasif glandular carcinoma were diagnosed.
  • It makes a minutious study of the cervix and diminishes the rate of false negative made by the cervical smear.
  • [MeSH-major] Colposcopy. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Biopsy. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / pathology. Female. Humans. Middle Aged. Neoplasm Invasiveness. Polyps / pathology. Prospective Studies. Sexual Behavior. Uterine Cervical Diseases / pathology. Uterine Cervical Dysplasia / pathology. Uterine Cervicitis / pathology. Vaginitis / pathology


65. Sanati S, Huettner P, Ylagan LR: Role of ProExC: a novel immunoperoxidase marker in the evaluation of dysplastic squamous and glandular lesions in cervical specimens. Int J Gynecol Pathol; 2010 Jan;29(1):79-87
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of ProExC: a novel immunoperoxidase marker in the evaluation of dysplastic squamous and glandular lesions in cervical specimens.
  • Our purpose was to evaluate the sensitivity, specificity, and predictive value of ProExC in dysplastic squamous and glandular lesions of the cervix.
  • Nine low-grade squamous intraepithelial lesion, 35 high-grade squamous intraepithelial lesion, 23 squamous metaplasia, and 14 adenocarcinoma in situ specimens were retrieved from our hospital files.
  • ProExC had sensitivity, specificity, and positive and negative predictive value of 89%, 100%, 100%, and 82%, respectively, for distinguishing high-grade squamous intraepithelial lesion from squamous metaplasia, and 93%, 100%, 100%, and 98%, respectively, for distinguishing adenocarcinoma in situ from reactive benign endocervix.
  • ProExC is a valuable marker for distinguishing dysplastic squamous and endocervical lesions of the cervix from squamous metaplasia in histologic sections.
  • ProExC may eventually be used in conjunction with morphologic and human papillomavirus evaluation for better classification of indeterminate cervical lesions in Papanicolaou smears.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cervical Intraepithelial Neoplasia / diagnosis. Immunoenzyme Techniques. Uterine Cervical Dysplasia / diagnosis. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952938.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


66. Medeiros F, Bell DA: Pseudoneoplastic lesions of the female genital tract. Arch Pathol Lab Med; 2010 Mar;134(3):393-403

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several of the more common pseudoneoplastic lesions are discussed in this article, including microglandular hyperplasia of the cervix mimicking well-differentiated endometrial adenocarcinoma, reactive epithelial changes in the fallopian tubes mimicking adenocarcinoma or carcinoma in situ, and pregnancy changes in the ovary including pregnancy luteoma and large solitary luteinized follicular cyst of pregnancy and puerperium that may mimic ovarian neoplasms.
  • Awareness of the features of such lesions will aid in their correct diagnosis and prevent overtreatment of benign processes.
  • [MeSH-major] Genital Diseases, Female / diagnosis. Granuloma, Plasma Cell / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Genital Neoplasms, Female / classification. Genital Neoplasms, Female / diagnosis. Humans. Pregnancy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20196667.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 76
  •  go-up   go-down


67. McCluggage WG: Immunohistochemistry as a diagnostic aid in cervical pathology. Pathology; 2007 Feb;39(1):97-111
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry as a diagnostic aid in cervical pathology.
  • As with biopsies from other sites in the female genital tract, immunohistochemistry is now being increasingly used in cervical pathology as an aid to diagnosis.
  • In this review, I discuss applications of immunohistochemistry in diagnostic cervical pathology with a particular focus on recent developments.
  • Although much of this review focuses on glandular lesions, the value of markers, such as MIB1 and p16, in the assessment of pre-invasive cervical squamous lesions is discussed.
  • In the broad field of cervical glandular lesions, topics covered include: the value of markers such as MIB1, p16 and bcl-2 in distinguishing adenocarcinoma in situ and glandular dysplasia from benign mimics; markers of mesonephric lesions, including CD10; markers of value in the diagnosis of minimal deviation adenocarcinoma, such as HIK1083; markers of value in distinguishing metastatic cervical adenocarcinoma in the ovary from primary ovarian endometrioid or mucinous adenocarcinoma.
  • Rarely ectopic prostatic tissue occurs in the cervix, which can be confirmed by positive staining with prostatic markers.
  • A panel of markers, comprising oestrogen receptor, vimentin, monoclonal carcinoembryonic antigen and p16, is of value in distinguishing between a cervical adenocarcinoma and an endometrial adenocarcinoma of endometrioid type.
  • Markers of use in the diagnosis of cervical neuroendocrine neoplasms, including small cell and large cell neuroendocrine carcinoma, are discussed.
  • It is stressed that small cell neuroendocrine carcinomas may be negative with most of the commonly used neuroendocrine markers and this does not preclude the diagnosis. p63, a useful marker of squamous neoplasms within the cervix, is of value in distinguishing small cell neuroendocrine carcinoma (p63 negative) from small cell squamous carcinoma (p63 positive) and in confirming that a poorly differentiated carcinoma is squamous in type.
  • [MeSH-major] Biomarkers, Tumor / analysis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17365826.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 104
  •  go-up   go-down


68. Tarkkanen J, Auvinen E, Nieminen P, Malmi R, Vartiainen J, Timonen T, Laurila P, Räisänen I, Unnerus HA, Sakki A, Mattila P, Van Den Brule AV, Tapper AM: HPV DNA testing as an adjunct in the management of patients with low grade cytological lesions in Finland. Acta Obstet Gynecol Scand; 2007;86(3):367-72
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 5/97 (5.2%) high grade lesions, which were HC2-negative but pap-positive, including 1 cervical adenocarcinoma in situ.
  • One CIN3 and one AIS remained HPV negative.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / diagnosis. DNA, Viral / analysis. Papillomaviridae / isolation & purification. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17364315.001).
  • [ISSN] 0001-6349
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


69. van de Nieuwenhof HP, Massuger LF, de Hullu JA, van Ham MA, van Dijck JA, Siebers AG, Bekkers RL: Significant decrease of adenocarcinoma in situ not reflected in cervical adenocarcinoma incidence in the Netherlands 1989-2003. Br J Cancer; 2008 Jan 15;98(1):165-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant decrease of adenocarcinoma in situ not reflected in cervical adenocarcinoma incidence in the Netherlands 1989-2003.
  • Over the period 1989-2003, the incidence of cervical adenocarcinoma (n=1615) was stable whereas that of cervical adenocarcinoma in situ (n=1884) significantly decreased (P=0.008), mainly caused by adenocarcinoma in situ lesions with a concurrent squamous dysplasia.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma in Situ / epidemiology. Carcinoma, Squamous Cell / epidemiology. Uterine Cervical Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):97-105 [10926787.001]
  • [Cites] Cell Oncol. 2007;29(1):19-24 [17429138.001]
  • [Cites] CMAJ. 2001 Apr 17;164(8):1151-2 [11338801.001]
  • [Cites] Lancet. 2001 May 12;357(9267):1490-3 [11377601.001]
  • [Cites] Int J Gynecol Pathol. 2002 Oct;21(4):314-26 [12352181.001]
  • [Cites] Cancer. 2002 Dec 25;96(6):330-7 [12478680.001]
  • [Cites] Br J Cancer. 2003 Sep 1;89(5):886-90 [12942122.001]
  • [Cites] Obstet Gynecol. 2003 Oct;102(4):765-73 [14551007.001]
  • [Cites] Cancer. 2003 Dec 25;99(6):336-41 [14681940.001]
  • [Cites] Cancer. 2004 Mar 1;100(5):1035-44 [14983500.001]
  • [Cites] J Clin Pathol. 1986 Jan;39(1):22-8 [3950029.001]
  • [Cites] Gynecol Oncol. 1990 Feb;36(2):246-9 [2298414.001]
  • [Cites] Obstet Gynecol. 1995 Jun;85(6):1017-21 [7770247.001]
  • [Cites] Int J Epidemiol. 1996 Apr;25(2):252-8 [9119549.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):166-70 [8995568.001]
  • [Cites] Int J Gynecol Pathol. 1997 Apr;16(2):103-10 [9100062.001]
  • [Cites] Obstet Gynecol. 1997 Sep;90(3):448-52 [9277660.001]
  • [Cites] Int J Cancer. 1998 Feb 9;75(4):536-45 [9466653.001]
  • [Cites] Obstet Gynecol. 1998 Jun;91(6):969-72 [9611006.001]
  • [Cites] Am J Clin Pathol. 1998 Aug;110(2):200-9 [9704619.001]
  • [Cites] J Clin Pathol. 1999 Feb;52(2):112-7 [10396238.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):159-66 [10487628.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):55-61 [10502426.001]
  • [Cites] Cancer Detect Prev. 2004;28(6):461-4 [15582270.001]
  • [Cites] Int J Cancer. 2005 Mar 1;113(6):1005-9 [15515017.001]
  • [Cites] Br J Cancer. 2005 Aug 8;93(3):376-8 [16012518.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2191-9 [16172231.001]
  • [Cites] Int J Gynecol Pathol. 2005 Oct;24(4):399-403 [16175089.001]
  • [Cites] Acta Obstet Gynecol Scand. 2006;85(1):106-11 [16521689.001]
  • [Cites] Int J Cancer. 2007 Jan 15;120(2):362-7 [17072843.001]
  • [Cites] J Reprod Med. 2000 Aug;45(8):613-5 [10986677.001]
  • (PMID = 18182979.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2359688
  •  go-up   go-down


70. Saqi A, Gupta PK, Erroll M, Babiac A, Blackmun D, Mansukhani M, Vazquez M: High-risk human papillomavirus DNA testing: a marker for atypical glandular cells. Diagn Cytopathol; 2006 Mar;34(3):235-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cervical/endocervical cytology screening has decreased morbidity and mortality, and implementing adjunctive human papilloma virus (HPV) DNA testing for atypical squamous cells of undetermined significance has improved the specificity for detecting premalignant squamous lesions.
  • Currently, there are no guidelines to perform HPV DNA testing on cervical/endocervical ThinPreps with atypical glandular cells (AGC).
  • To assess the potential role of HPV DNA testing on AGC cases, Hybrid Capture 2 (Digene Corp.) testing was performed on 144 cervical/endocervical AGC specimens.
  • Of 43 HPV-positive patients, 37 had adenocarcinoma in situ (AIS), atypical squamous cells of undetermined significance (ASCUS), or cervical squamous intraepithelial neoplasia, while only one patient without high-risk HPV had a squamous intraepithelial neoplasia.
  • Furthermore, most high-risk HPV positive AGC cases harbored high-grade squamous intraepithelial lesion (HSIL) rather than AIS.
  • Our data support HPV DNA testing of all AGC specimens to detect cervical, especially squamous, neoplasia.
  • [MeSH-major] Cervix Uteri / virology. DNA, Viral / analysis. Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. DNA Probes, HPV. Female. Genetic Markers. Humans. Neoplasms, Squamous Cell / chemistry. Neoplasms, Squamous Cell / diagnosis. Neoplasms, Squamous Cell / pathology. Risk Factors. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • (PMID = 16470857.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Probes, HPV; 0 / DNA, Viral; 0 / Genetic Markers
  •  go-up   go-down


71. Frank JE: The colposcopic examination. J Midwifery Womens Health; 2008 Sep-Oct;53(5):447-52
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colposcopy is used to evaluate women with genital tract abnormalities and abnormal cervical cytology.
  • It is an office-based procedure during which the cervix is examined under illumination and magnification before and after application of dilute acetic acid.
  • Endocervical sampling may accompany colposcopy, particularly in the evaluation of nonpregnant women with cytology results of atypical glandular cells and adenocarcinoma in situ.
  • [MeSH-major] Cervix Uteri / pathology. Colposcopy / methods
  • [MeSH-minor] Adolescent. Biopsy. Female. Humans. Midwifery. Physical Examination. Postmenopause. Pregnancy. Uterine Cervical Diseases / diagnosis. Vaginal Diseases / diagnosis


72. Lai HC, Lin YW, Huang RL, Chung MT, Wang HC, Liao YP, Su PH, Liu YL, Yu MH: Quantitative DNA methylation analysis detects cervical intraepithelial neoplasms type 3 and worse. Cancer; 2010 Sep 15;116(18):4266-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative DNA methylation analysis detects cervical intraepithelial neoplasms type 3 and worse.
  • BACKGROUND: DNA methylation may be used a potential biomarker for detecting cervical cancer.
  • The authors of this report used quantitative methylation analysis of 4 genes in a full spectrum of cervical lesions to test its potential clinical application.
  • METHODS: This hospital-based, retrospective, case-control study was conducted in 185 patients and included patients who had a normal uterine cervix (n = 53), cervical intraepithelial neoplasm type 1 (CIN1) (n = 37), CIN2 (n = 22), CIN3 (n = 24), carcinoma in situ (CIS) (n = 22), squamous cell carcinoma (SCC, n = 20), and adenocarcinoma (AC) (n = 7).
  • RESULTS: The PMRs of the 4 genes were significantly higher in CIN3 and worse (CIN3+) lesions than the PMRs in specimens of normal cervix and CIN1 or CIN2 (P < .001).
  • CONCLUSIONS: The current results indicated that quantitative PCR-based testing for DNA methylation of 4 genes holds great promise for cervical cancer screening and warrants further population-based studies using standardized DNA methylation testing.
  • [MeSH-major] Biomarkers / analysis. Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / genetics. DNA Methylation. Polymerase Chain Reaction / methods

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Cancer Society.
  • (PMID = 20564139.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


73. Kałuzyński A, Olszak A, Smolarz B, Kowalczyk A, Kulig A: [Cervical glandular intraepithelial neoplasia topography and the risk of conisation]. Ginekol Pol; 2005 Oct;76(10):763-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cervical glandular intraepithelial neoplasia topography and the risk of conisation].
  • OBJECTIVES: The frequency of endocervical adenocarcinoma is increasing in comparison with squamous cell carcinoma and it presents a very difficult diagnostic and therapeutic problem.
  • 1) Evaluation of topography of the cervical glandular intraepithelial neoplasia (CGIN) 2) An analysis of the Human Papillomavirus (HPV) infection rate in samples.
  • MATERIALS AND METHODS: 360 amputated uterine cervix samples with histologically-proven diagnosis of cervical intraepithelial neoplasia (CIN-3) were evaluated.
  • RESULTS: Among 360 positive cervical intraepithelial glandular neoplasia samples (CIN-3) 71 (19.7%) showed coexisting glandular lesions (CGIN-1, 2, 3).
  • The lesions in endocervical glandular cells of CIGN-type were distributed from the distance up to 14 mm from the surface of cervix.
  • CIN-3 is associated in about 20% with cervical glandular intraepithelial neoplasia (CGIN).
  • [MeSH-major] Cervical Intraepithelial Neoplasia / pathology. Conization. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Carcinoma in Situ / pathology. Female. Humans. Papillomaviridae / isolation & purification. Polymerase Chain Reaction. Precancerous Conditions / pathology. Retrospective Studies


74. Haidopoulos DA, Stefanidis K, Rodolakis A, Pilalis A, Symiakaki I, Diakomanolis E: Histologic implications of Pap smears classified as atypical glandular cells. J Reprod Med; 2005 Jul;50(7):539-42
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: Cervical cytology smears reported as AGC were reviewed and correlated with histologic follow-up.
  • Of these, 64 were classified as AGC not otherwise specified (NOS) (56.6%), 48 AGC favor neoplasia (42.5%) and 1 (0.9%) adenocarcinoma in situ.
  • Of these patients, 14 (12.4%) had endometrial involvement, whereas cervical abnormalities were identified in the remaining 16 (14.1%).
  • Older women were more likely to have involvement of the endometrium and younger women, involvement of the cervix.
  • [MeSH-major] Cervix Uteri / cytology. Cervix Uteri / pathology. Papanicolaou Test. Vaginal Smears
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adult. Age Factors. Aged. Aged, 80 and over. Diagnosis, Differential. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / pathology. Female. Humans. Middle Aged. Retrospective Studies. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology


75. Ronnett BM, Yemelyanova AV, Vang R, Gilks CB, Miller D, Gravitt PE, Kurman RJ: Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. Am J Surg Pathol; 2008 Dec;32(12):1835-53
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms.
  • In 18 cases, the cervical tumors were clearly invasive; these included 5 clinically evident tumors diagnosed before the ovarian metastases (immediately preoperatively to 7 y), 11 clinically unsuspected tumors diagnosed concurrently in specimens obtained for evaluation of ovarian/pelvic masses, 1 case with concurrent clinically evident cervical and ovarian masses, and 1 clinically occult tumor diagnosed subsequent to the ovarian metastasis.
  • In 11 cases, the cervical tumors were more limited; these included 5 tumors comprised predominantly of adenocarcinoma in situ with small foci of superficial invasion ("microinvasive carcinomas") diagnosed before the ovarian metastases (3 mo to 7 y) and 6 tumors comprised of extensive adenocarcinoma in situ lacking unequivocally recognizable stromal invasion diagnosed before (9 mo to 7 y, n=4), concurrently with (n=1), or subsequent to (n=1) the ovarian metastases.
  • Fifteen cervical tumors involved lower uterine segment corpus endometrium or endomyometrium, including 4 tumors that were minimally invasive or not recognizably invasive in the cervix.
  • Endocervical adenocarcinomas, including microinvasive forms and some not recognizably invasive, have the potential to metastasize to the ovaries; extension into the lower uterine segment/corpus endometrium may be a risk factor, with retrograde uterine/transtubal spread as a possible mechanism.
  • [MeSH-major] Adenocarcinoma / secondary. Ovarian Neoplasms / secondary. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Cyclin-Dependent Kinase Inhibitor p16 / metabolism. DNA, Viral / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. In Situ Hybridization. Middle Aged. Papillomavirus Infections / complications. Papillomavirus Infections / epidemiology. Polymerase Chain Reaction. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18813124.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


76. Kumar N, Bongiovanni M, Molliet MJ, Pelte MF, Egger JF, Pache JC: Diverse glandular pathologies coexist with high-grade squamous intraepithelial lesion in cyto-histological review of atypical glandular cells on ThinPrep specimens. Cytopathology; 2009 Dec;20(6):351-8
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To identify in cytology, high-grade squamous intraepithelial lesions with endocervical glandular extension in cases previously diagnosed as atypical glandular cells (AGC), analyse possible reasons for the diagnostic pitfall and document the frequency of glandular pathology coexisting with high-grade cervical intraepithelial lesion in histology.
  • METHODS: Thirty-nine ThinPrep cervical smear (Pap) tests reported as AGC of undetermined significance and showing high-grade lesions on histology [cervical intraepithelial neoplasia (CIN) 2 or 3, endometrial or extrauterine adenocarcinoma] were reviewed retrospectively to identify the cases of high-grade squamous intraepithelial lesion with endocervical glandular extension, using the Bethesda 2001 system.
  • RESULTS: A high frequency of diverse glandular pathologies coexisted with high-grade cervical intraepithelial lesions on histology.
  • This included endocervical glandular extension in 63%, benign glandular pathology in 33% and pre-neoplastic or malignant glandular pathology (endocervical glandular dysplasia, adenocarcinoma in situ and metastatic breast carcinoma) in 17% cases.
  • The identification of endocervical glandular extension on cervical cytology would alert the gynaecologist to perform a thorough assessment of the endocervix during colposcopy.
  • [MeSH-major] Cervical Intraepithelial Neoplasia. Cervix Uteri / pathology. Cytological Techniques. Neoplasms, Glandular and Epithelial. Uterine Cervical Neoplasms
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Precancerous Conditions / diagnosis. Precancerous Conditions / pathology. Retrospective Studies. Sensitivity and Specificity. Young Adult


77. Dalla Nora LC, Azara CZ, Pace EL, Martins CM, Zeferino LC, Westin MC, Derchain SF, Rabelo-Santos SH: Cytomorphological criteria, subclassifications of endocervical glandular cell abnormalities, and histopathological outcome: a frequency study. Diagn Cytopathol; 2010 Nov;38(11):806-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this study was to evaluate the frequency and the significance of cytomorphological criteria defined in studies as being predictive of neoplasia in cervical smears of women with a cytological diagnosis of atypical glandular cells (AGC) or adenocarcinoma in situ (AIS).
  • Women (n = 103) with cytological findings suggestive of AGC or AIS, whose diagnoses were later established by histopathology, were included in the study.
  • The criteria analyzed and classified as present or absent in cervical smears previously classified as AGC-NOS (not otherwise specified), AGC-FN (favor neoplasia), or AIS were as follows: irregular nuclear membranes; scanty cytoplasm; dyskeratotic cells; increased nuclear/cytoplasmic ratio; nucleoli; overlapping; papillary clusters, feathering; loss of polarity; nuclear enlargement; coarsely granular chromatin; and pseudostratified strips.
  • Coarsely granular chromatin was observed in 62.5% of cases with a diagnosis of neoplasia.
  • Feathering was present in 80% of cases of histopathological AIS.
  • Loss of polarity and coarsely granular chromatin were significantly associated with neoplastic diagnosis considering all subcategories of glandular abnormalities diagnosis.
  • In AGC-SOE subclassification, coarsely granular chromatin was significantly associated with neoplastic diagnosis.
  • The presence of nucleoli was significantly associated with neoplastic diagnosis in cervical smears qualified as AGC-FN and AIS.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / pathology. Uterine Cervical Neoplasms / pathology


78. Yemelyanova A, Vang R, Seidman JD, Gravitt PE, Ronnett BM: Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor. Am J Surg Pathol; 2009 Jun;33(6):914-24
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor.
  • Determining the primary site of a uterine adenocarcinoma can be problematic in hysterectomy specimens due to the overlapping morphology of endocervical adenocarcinomas and endometrial carcinomas, particularly when both the corpus (usually lower uterine segment) and endocervix are involved and precursor lesions are lacking or difficult to distinguish from intramucosal spread of carcinoma from one site to the other.
  • Both preferential extension of endocervical adenocarcinomas into the endometrium (rather than deep cervical stroma) and myometrial invasion derived from the endometrial component are rarely encountered; to our knowledge, these unusual patterns of spread have not been detailed in prior reports.
  • Six cases had limited amounts of tumor in the cervix proper, with depths of invasion no greater than 5 mm in 4 and only adenocarcinoma in situ in 2.
  • Four cases had cervical stromal invasion of more than 5 mm but all of these had greater amounts of horizontal extension into endometrium or endomyometrium.
  • Five tumors were originally diagnosed as primary endometrial carcinoma with either cervical extension or concurrent endocervical adenocarcinoma in situ.
  • HPV DNA was detected in both the cervical and corpus components in all tumors and all exhibited diffuse/strong p16 expression and decreased or absent expression of hormone receptors.
  • These ancillary techniques are useful for clarifying the origin of uterine adenocarcinomas when morphologic features and tumor location are equivocal.
  • These cases illustrate that dominant uterine corpus involvement (endometrial or endomyometrial) by primary endocervical adenocarcinoma can lead to misclassification as primary endometrial adenocarcinoma with cervical extension (Fédération Internationale de Gynécologie et d'Obstétrique stage II), especially when endometrial extension of endocervical adenocarcinoma simulates complex atypical hyperplasia.
  • A subset of misclassified endocervical adenocarcinomas may account for some HPV-positive uterine carcinomas reported as primary endometrial carcinomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. DNA, Viral / analysis. Endometrial Neoplasms / diagnosis. Receptors, Steroid / biosynthesis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Endometrium / metabolism. Endometrium / pathology. Endometrium / virology. Female. Humans. Immunohistochemistry. In Situ Hybridization. Middle Aged. Papillomaviridae. Papillomavirus Infections / diagnosis. Papillomavirus Infections / metabolism. Papillomavirus Infections / pathology. Receptors, Estrogen / biosynthesis. Receptors, Progesterone / biosynthesis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19295407.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Receptors, Steroid
  •  go-up   go-down


79. Eichhorn JH, Brauns TA, Gelfand JA, Crothers BA, Wilbur DC: A novel automated screening and interpretation process for cervical cytology using the internet transmission of low-resolution images: a feasibility study. Cancer; 2005 Aug 25;105(4):199-206
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel automated screening and interpretation process for cervical cytology using the internet transmission of low-resolution images: a feasibility study.
  • BACKGROUND: Transmission over the Internet of low-resolution images acquired by automated screening of cervical cytology specimens has the potential to provide remote interpretation and, hence, centralization of a cytology workforce.
  • METHODS: Liquid-based cervical cytology slides were scanned using the FocalPoint(R) System.
  • Ten black-and-white images that had the greatest probability of containing abnormality were acquired from each of 32 reference slides (16 negative samples, 3 samples of atypical squamous cells of uncertain significance, 5 samples of low-grade squamous intraepithelial lesions [LSIL], 5 samples of high-grade squamous intraepithelial lesions [HSIL], 1 adenocarcinoma in situ sample, and 2 carcinoma samples) and were transmitted as e-mail attachments in JPEG format to remote reading stations.
  • The procedure may represent an effective way to centralize cervical cytology services and to allow the provision of services to previously unscreened populations that lack an effective cytology infrastructure.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Neoplasms, Squamous Cell / diagnosis. Telepathology / methods. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears
  • [MeSH-minor] Automation. Cervix Uteri / pathology. Diagnosis, Differential. Feasibility Studies. Female. Humans. Internet. Papillomaviridae. Papillomavirus Infections / diagnosis. Reproducibility of Results. Signal Processing, Computer-Assisted


80. van der Aa MA, Helmerhorst TJ, Siesling S, Riemersma S, Coebergh JW: Vaginal and (uncommon) cervical cancers in the Netherlands, 1989-2003. Int J Gynecol Cancer; 2010 May;20(4):638-45
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaginal and (uncommon) cervical cancers in the Netherlands, 1989-2003.
  • BACKGROUND: The clinical and prognostic evaluation of cervical and vaginal tumors other than squamous cell and adenocarcinomas is hampered by the low incidence, and clinical and epidemiological studies on these uncommon tumors are scarce.
  • Having close affinity with the pathology laboratories, the Netherlands Cancer Registry offers a great opportunity to study frequency, stage, treatment, and survival of uncommon tumors in the cervix and vagina and separately, the clear cell adenocarcinoma of the vagina and cervix.
  • METHODS: All invasive cervical tumors (n = 10,570) and all in situ and invasive vaginal tumors (n = 778) diagnosed in the Netherlands during 1989-2003 were selected from the Netherlands Cancer Registry.
  • Age, stage at diagnosis, and treatment were described for each histological subgroup to find differences between common and uncommon tumors, including 5-year relative survival rates.
  • RESULTS: Twenty-five patients (3%) with cervical cancer subsequently developed a vaginal tumor (during 1989-2003), and 19 of these patients underwent hysterectomy for their cervical cancer.
  • A significantly worse prognosis was found for patients with small cell neuroendocrine cervical tumors and for patients with vaginal melanomas.
  • Patients with clear cell adenocarcinoma of the vagina and cervix were found across all age categories.
  • CONCLUSIONS: The less common histological types of cervical and vaginal cancers were clearly different from squamous cell carcinomas, especially with respect to age at diagnosis and survival rates.
  • [MeSH-major] Adenocarcinoma / mortality. Carcinoma, Squamous Cell / mortality. Neoplasms, Glandular and Epithelial / mortality. Uterine Cervical Neoplasms / mortality. Vaginal Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20686385.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Luyten A, Scherbring S, Reinecke-Lüthge A, Braun BE, Pietralla M, Theiler K, Petry KU: Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years. J Clin Virol; 2009 Nov;46 Suppl 3:S5-10
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.
  • BACKGROUND: Currently, the German cervical cancer screening program encompasses an annual cytological Papanicolaou (Pap) smear.
  • However, primary screening for cervical cancer using human papillomavirus (HPV) DNA testing detects cervical pre-cancerous lesions with a significantly higher sensitivity than the Pap smear-based cytology.
  • OBJECTIVES: In order to develop viable modalities for primary cervical screening incorporating DNA testing for high-risk (HR) types of HPV, we started a pilot project in the city of Wolfsburg, Germany, in February 2006.
  • There were 417 (2.48%) women referred for colposcopy, 104 of whom were diagnosed with cervical intraepithelial neoplasia (CIN) 3 or worse, including 8 invasive cancers and 8 adenocarcinoma in situ (ACIS).
  • CONCLUSIONS: The presented risk-adapted Wolfsburg Cervical Cancer Prevention Project ("Wolfsburg Model") has been shown to be effective and feasible in identifying women at risk and for avoiding unnecessary procedures for those who are double negative, thus allowing longer screening intervals and cost savings.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / diagnosis. Mass Screening / methods. Papillomavirus Infections / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Alphapapillomavirus / genetics. Alphapapillomavirus / isolation & purification. Cervix Uteri / pathology. Cervix Uteri / virology. Colposcopy. DNA, Viral / genetics. DNA, Viral / isolation & purification. Early Detection of Cancer / economics. Early Detection of Cancer / methods. Female. Germany. Humans. Middle Aged. Papanicolaou Test. Pilot Projects. Risk. Time Factors. Vaginal Smears


82. Chen L, Yang B: Assessment of reflex human papillomavirus DNA testing in patients with atypical endocervical cells on cervical cytology. Cancer; 2008 Aug 25;114(4):236-41
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of reflex human papillomavirus DNA testing in patients with atypical endocervical cells on cervical cytology.
  • BACKGROUND: Reflex human papillomavirus (HPV) testing for atypical squamous cells of undetermined significance (ASC-US) has improved the sensitivity and specificity in detecting high-grade squamous dysplasia (cervical intraepithelial neoplasia [CIN]2+).
  • This report is of a 5-year experience with reflex HPV testing in women with AEC and assessment of the potential role of reflex HPV testing in guiding subsequent colposcopy-directed cervical biopsy/curettage in a large tertiary care hospital setting.
  • The most severe histopathologic diagnosis was recorded.
  • Histopathologic examination of the 64 HPV-positive AEC cases revealed 18 cases of endocervical adenocarcinoma in situ/adenocarcinoma (AIS+) and 22 cases of CIN2+.
  • Among 253 of the HPV-negative AEC women, AIS+ was found in only 3 cases and CIN2+ in 1 case.
  • Cervical AIS+ was found in 28% of the HPV-positive AEC patients and in only 0.9% of the HPV-negative patients (P<.0001).
  • When the significant glandular (AIS+) and squamous (CIN2+) lesions were combined, 62.5% of the lesions were detected in HPV-positive AEC cases compared with 1.6% in the HPV-negative AEC cases (P<.0001).
  • CONCLUSIONS: Because of a high sensitivity (91.0%) and high specificity (91.2%) in detecting significant cervical lesions, reflex HPV testing for cytologic diagnosis of AEC appears to be a useful ancillary tool in the selection of high-risk patients for colposcopy.
  • [MeSH-major] Cervix Uteri / pathology. DNA, Viral / analysis. Papanicolaou Test. Papillomaviridae / isolation & purification. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears
  • [MeSH-minor] Adult. Aged. Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / pathology. Female. Follow-Up Studies. Humans. Middle Aged. Retrospective Studies. Sensitivity and Specificity


83. Apgar BS, Kittendorf AL, Bettcher CM, Wong J, Kaufman AJ: Update on ASCCP consensus guidelines for abnormal cervical screening tests and cervical histology. Am Fam Physician; 2009 Jul 15;80(2):147-55
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on ASCCP consensus guidelines for abnormal cervical screening tests and cervical histology.
  • New data have emerged since publication of the American Society for Colposcopy and Cervical Pathology's 2001 consensus guidelines for management of abnormal cervical cytology and histology.
  • Human papillomavirus testing is now included for management of atypical glandular cytology, for follow-up after treatment for cervical intraepithelial neoplasia, and in combination with cytologic screening in women 30 years and older.
  • Cervical intraepithelial neoplasia, grade 1 can be managed conservatively in adult women, but treatment for cervical intraepithelial neoplasia, grades 2 and 3 is recommended.
  • Conservative management of adolescents with any cytologic or histologic diagnosis except specified cervical intraepithelial neoplasia, grade 3 and adenocarcinoma in situ is recommended.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / diagnosis. Cervix Uteri / pathology. Precancerous Conditions / diagnosis. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears
  • [MeSH-minor] Adolescent. Adult. Alphapapillomavirus / genetics. Colposcopy. DNA, Viral / analysis. Female. Humans. Papillomavirus Infections / diagnosis. Young Adult


84. FUTURE II Study Group: Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis; 2007 Nov 15;196(10):1438-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A quadrivalent (types 6, 11, 16, and 18) human papillomavirus (HPV) L1 virus-like-particle (VLP) vaccine has been shown to be 95%-100% effective in preventing cervical and genital disease related to HPV-6, -11, -16, and -18 in 16-26-year-old women naive for HPV vaccine types.
  • RESULTS: Vaccination was 100% effective (95% confidence interval [CI], 79%-100%) in preventing incident cervical intraepithelial neoplasia 2 or 3 or cervical adenocarcinoma in situ caused by the HPV type or types for which the women were negative at enrollment.
  • [MeSH-minor] Adolescent. Adult. Antibodies, Viral / blood. Cervical Intraepithelial Neoplasia / prevention & control. Cervical Intraepithelial Neoplasia / virology. DNA, Viral / analysis. Double-Blind Method. Enzyme-Linked Immunosorbent Assay. Female. Humans. Injections, Intramuscular. Polymerase Chain Reaction. Prospective Studies. Treatment Outcome. Uterine Cervical Neoplasms / prevention & control. Uterine Cervical Neoplasms / virology

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Infect Dis. 2007 Nov 15;196(10):1431-2 [18008218.001]
  • (PMID = 18008221.001).
  • [ISSN] 0022-1899
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / DNA, Viral; 0 / Papillomavirus Vaccines
  •  go-up   go-down


85. Gurbuz A, Karateke A, Kabaca C, Kir G: Atypical glandular cells: improvement in cytohistologic correlation by the 2001 Bethesda system. Int J Gynecol Cancer; 2005 Sep-Oct;15(5):903-10
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cytology files of 18,955 patients were reviewed for diagnosis of atypical glandular cells of undetermined significance (AGUS), and histopathology files were searched.
  • Cervical smears of these patients were reclassified according to TBS 2001.
  • In reevaluation according to TBS 2001, 31 specimens were reevaluated as atypical glandular cells (AGC) and 3 were reevaluated as adenocarcinoma in situ, 8 as AGC with concomitant squamous cell abnormalities, 1 as atypical squamous cells that cannot exclude high-grade squamous intraepithelial lesions, and 33 as negative.
  • [MeSH-major] Cervix Uteri / pathology. Papanicolaou Test. Uterine Cervical Diseases / diagnosis. Uterine Cervical Diseases / pathology. Vaginal Smears / methods


86. Costa S, Negri G, Sideri M, Santini D, Martinelli G, Venturoli S, Pelusi C, Syrjanen S, Syrjanen K, Pelusi G: Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix. Gynecol Oncol; 2007 Jul;106(1):170-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix.
  • OBJECTIVE: The present study assessed (i) the clinical outcome of patients with conservatively treated cervical adenocarcinoma in situ (AIS), (ii) the accuracy of diagnosing AIS by cytology, colposcopy and histology, as well as (iii) the performance of cervical cytology and HPV testing in detection of residual or recurrent disease after conservatively treated AIS.
  • METHODS: A series of 42 consecutive women (mean age 40.5 years; range 27-63 years) underwent conservative (cone) treatment of AIS and were prospectively followed up for a mean of 40 months (median 42 months), using colposcopy, PAP smear, biopsy and HPV testing (with hybrid capture II) repeated at 6-month intervals.
  • Twenty four patients (57.1%) had AIS as a pure lesions and 18 combined with squamous cell lesion (four had invasive SCC).
  • In four patients, an adenocarcinoma (AdCa) stage IA1 was diagnosed during the follow-up.
  • CONCLUSIONS: These results suggest that HR-HPV test in conjunction with cytology offers clear advantages over single cytology in monitoring the women conservatively treated for cervical AIS.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / virology. Papillomavirus Infections / pathology. Papillomavirus Infections / virology. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Adult. Carcinoma in Situ. Conization. DNA, Viral / analysis. Female. Follow-Up Studies. Humans. Middle Aged. Papanicolaou Test. Papillomaviridae / genetics. Predictive Value of Tests. Treatment Outcome. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17481701.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


87. Puebla-Mora AG, Heras A, Cano-Valdez AM, Domínguez-Malagón H: Human telomerase and alpha-methylacyl-coenzyme A racemase in prostatic carcinoma. A comparative immunohistochemical study. Ann Diagn Pathol; 2006 Aug;10(4):205-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human telomerase detected by in situ hybridization has been demonstrated to be a useful tool for the diagnosis of malignancy and has also been tested by reverse transcriptase-polymerase chain reaction in several tumors such as hepatic cell carcinoma, melanoma, colonic carcinoma, gastric carcinoma, biliary carcinoma, breast carcinoma, mesothelioma, lung carcinoma, female tract carcinoma, and prostatic carcinoma.
  • Carcinomas of cervix, endometrium, and breast have been studied by this method, but its value in prostatic carcinoma has not been explored; for that reason, we studied benign and malignant prostatic lesions by immunohistochemistry using paraffin embedded tissue.
  • [MeSH-major] Adenocarcinoma / enzymology. DNA-Binding Proteins / metabolism. Immunoenzyme Techniques / methods. Prostatic Intraepithelial Neoplasia / enzymology. Prostatic Neoplasms / enzymology. Racemases and Epimerases / metabolism. Telomerase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844561.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; EC 2.7.7.49 / Telomerase; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


88. Fambrini M, Pieralli A, Taddei GL, Penna C: Laser cylindrical excision for cervical adenocarcinoma in situ. Int J Gynaecol Obstet; 2006 Dec;95(3):292-3
Hazardous Substances Data Bank. Carbon dioxide .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laser cylindrical excision for cervical adenocarcinoma in situ.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma in Situ / surgery. Conization / methods. Laser Therapy / methods. Neoplasm Recurrence, Local. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16999959.001).
  • [ISSN] 0020-7292
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 142M471B3J / Carbon Dioxide
  •  go-up   go-down


89. Modem RR, Otis CN, Florence RR, Pantanowitz L: Intestinal type adenocarcinoma in situ of the cervix. Diagn Cytopathol; 2007 Sep;35(9):584-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal type adenocarcinoma in situ of the cervix.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma in Situ / pathology. Intestinal Neoplasms / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Cytological Techniques. Diagnosis, Differential. Female. Humans. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17703459.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Baydar DE, Himmetoglu C: Test and Teach. Abnormal glands in the uterine cervix Part 1. Diagnosis: Ectopic prostate tissue in the uterine cervix. Pathology; 2008 Jun;40(4):407-8
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Test and Teach. Abnormal glands in the uterine cervix Part 1. Diagnosis: Ectopic prostate tissue in the uterine cervix.
  • [MeSH-major] Cervix Uteri / pathology. Choristoma / pathology. Prostate. Uterine Cervical Diseases / pathology
  • [MeSH-minor] Acid Phosphatase. Adenocarcinoma / diagnosis. Carcinoma in Situ / diagnosis. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Prostate-Specific Antigen / metabolism. Protein Tyrosine Phosphatases / metabolism. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cervix Disorders.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18446633.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


91. Selvaggi SM: Cytologic features of high grade squamous intraepithelial lesions involving endocervical glands on thin-layer cytology. Acta Cytol; 2005 Nov-Dec;49(6):689-90
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma in Situ / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Cervix Uteri / pathology. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears / methods
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Retrospective Studies. Sensitivity and Specificity






Advertisement